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 Abstract: Biomolecular changes associated with cancer 
progression can be identified using Raman spectroscopy, 
allowing for this technique to be utilized as a non-inva-
sive tool for the diagnosis of bladder cancer. Applications 
of Raman spectroscopy for diagnostics in real-time have 
consistently produced higher sensitivities and specifici-
ties than current clinical methods. This technique can 
be applied  in vivo during bladder visualization (cysto-
scopic) procedures as an  “ optical biopsy ” or  in vitro to 
cells obtained from urine cytology specimens. This review 
follows the evolution of studies in this field from the first 
 in vitro experiment to the most recent  in vivo application, 
identifies how diagnostic algorithms are developed, and 
provides molecular information associated with the etiol-
ogy of the biochemical continuum of disease progression. 
Future prospects for the application of Raman spectros-
copy in bladder cancer diagnostics are also discussed. 
 Keywords:  Raman microspectroscopy;  bladder;  cancer 
diagnostics;  Raman fiber-optic probe. 
 Zusammenfassung: Biomolekulare  Ä nderungen, die mit 
der Tumorprogression in Verbindung stehen, k ö nnen 
mittels Raman-Spektroskopie identifiziert werden, was 
es erlaubt dieses Verfahren als nicht-invasives Werkzeug 
zur Diagnose von Blasenkrebs zu verwenden. Raman-
Spektroskopie-Anwendungen f ü r die Diagnose in Echtzeit 
haben durchweg h ö here Empfindlichkeiten und Spezifit ä-
 ten als aktuelle klinische Methoden. Das Verfahren kann 
 in vivo w ä hrend einer Blasenspiegelung (Zystoskopie) als 
“optische Biopsie” oder  in vitro an Zellen, die aus einer 
Urin-Zytologie gewonnen wurden, eingesetzt werden. Der 
vorliegende Review-Artikel betrachtet die Entwicklung in 
diesem Bereich beginnend mit dem ersten  In-Vitro -Experi-
ment bis hin zu den neuesten  In-Vivo -Anwendungen, zeigt 
auf, wie Diagnose-Algorithmen entwickelt wurden und 
liefert molekulare Informationen, die mit der  Ä tiologie 
des biochemischen Kontinuums des Krankheitsverlaufs 
assoziiert sind. Au ß erdem werden die Zukunftsperspekti-
ven f ü r die Anwendung der Raman-Spektroskopie in der 
Blasenkrebs-Diagnostik diskutiert. 
 Schl ü sselw ö rter:  Raman-Mikrospektroskopie;  Blase; 
 Krebsdiagnostik;  faseroptische Raman-Sonde. 
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1   Introduction 
 Bladder cancer is the fourth most common cancer in men, 
with approximately 200 new cases diagnosed in men 
and women every day in the USA  [1] . As with most solid 
organ malignancies, early diagnosis, detection and treat-
ment are imperative for good clinical outcomes. Bladder 
diseases, such as bladder cancer, cystitis and bladder 
outlet obstruction, are most often diagnosed using inva-
sive procedures. Cystoscopy is the cornerstone of bladder 
diagnostics for real-time visualization of the bladder 
mucosa. However, by its nature it is an uncomfortable 
invasive procedure and is not without significant risk 
and potential complications. Urine cytology often serves 
as a useful non-invasive diagnostic adjunct in the diag-
nosis of bladder cancer. Examination of voided urine or 
bladder washing specimens for exfoliated cancer cells has 
high sensitivity in high-grade tumors but low sensitivity 
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in low-grade tumors  [2] . It has been shown that delays in 
the process of diagnosis leads to unsatisfactory outcomes 
and adverse effects for the patient involved  [3, 4] . There-
fore, there is a real clinical need to develop and integrate 
a non-invasive, sensitive and specific technique to assist 
in bladder cancer diagnosis and differentiation between 
low- and high-grade diseases. 
 Optical diagnostic tools in medicine are becoming 
more popular in recent times because they can provide 
fast, highly accurate results without damaging the bio-
logical samples with toxic chemical markers. Raman spec-
troscopy is one of the most promising optical diagnostic 
tools that can be applied to the urinary bladder as it is able 
to detect changes in the molecular composition of tissue 
samples in real time, which is not only useful for discrimi-
nating between different grades and stages of disease, but 
which may also provide epigenetic clues as to the etiology 
of the malignancy. This information is obtained by meas-
uring changes in the wavelength of light as it is scattered 
from the tissue (or cell) sample. Raman scattering occurs 
when an incident laser photon interacts with a molecular 
bond in the sample, and the emitted photon has a differ-
ent energy than the incident one, which results in a shift 
in the wavelength of the photon. This shift in wavelength 
provides information about the type of molecular bond 
present in the sample being interrogated. The Raman 
spectra obtained from tissue or cells can be inputted to 
trained statistical multivariate algorithms in order to diag-
nose bladder cancer with high sensitivity and specificity. 
The application of Raman spectroscopy for the detection 
of bladder disease is a highly accurate diagnostic tool that 
can be applied  in vivo ,  in vitro and  ex vivo using a variety 
of spectroscopic systems, which will be further discussed 
later. 
 This paper reviews the contributions over the past 
decade on the application of Raman spectroscopic tech-
niques for improving the accuracy of detecting bladder 
cancer and some other forms of bladder disease. The 
existence of review papers previously published in the 
application of Raman spectroscopy to urology  [5] and to 
cancer diagnostics in general  [6] are acknowledged. Here 
the focus is only on bladder disease which allows us to 
provide a significantly deeper level of detail on this subject 
matter. This paper is intended to be legible for both the 
biomedical physicist and the clinician. 
 The results achieved for the diagnosis of bladder 
cancer using Raman spectroscopy to date are significantly 
better than current clinical methods, particularly for 
urine cytology. Presently, white light cystoscopy, which 
is most often used to diagnose bladder cancer, has sen-
sitivities and specificities between 62 – 84% and 43 – 98%, 
respectively  [7] , whereas Raman-based cystoscopy has 
shown a sensitivity of 85% and specificity of 79% within 
the first  in vivo study  [8] , and sensitivity and specificity 
of 85.7% and 100% using a confocal fiber-optic probe  ex 
vivo  [9] . Fluorescence cystoscopy using 5-aminolevulinic 
acid (5-ALA) or its hexyl ester, hexaminolevulinate (HAL), 
has previously been shown to achieve sensitivities and 
specificities of 76 – 97% and 43 – 79% respectively  [10] ; 
when fluorescence and Raman spectroscopy modalities 
are combined, 100% sensitivity and specificity has been 
demonstrated  [11] . Urine cytology has the advantage of 
being entirely non-invasive but its low sensitivity, partic-
ularly for low-grade tumors, which represent the bulk of 
cases, has meant that it is generally not used as a primary 
diagnostic tool. For high-grade tumors, sensitivities of 
52 – 78% are obtained using urine cytology, but for low-
grade tumors, this sensitivity decreases significantly to 
0 – 50%. However, in the first patient study Raman cytol-
ogy has been shown to successfully diagnose between 
normal, low-grade and high-grade bladder cells with a 
sensitivity of 92% and specificity of 91%  [12] . Interesting 
new approaches such as modulated Raman spectroscopy 
have been successfully applied to bladder cancer cell 
lines  [13] and may hold the potential to further improve 
upon the diagnostic sensitivity and specificity of Raman 
cytology. 
 The breakdown of this paper is as follows:
 –  Firstly, an introduction to bladder pathology will 
be given in Section 2 with information on how 
bladder cancer is currently diagnosed and classified 
by pathologists based on histological grading or 
pathological staging systems, and also on how non-
malignant bladder diseases are identified. 
 –  This is followed by an introduction to Raman 
spectroscopy, the physics involved in this scattering 
process, and an explanation into why this technique 
can be utilized as a means of diagnosing bladder 
cancer in Section 3. There are three main spectroscopic 
systems associated with the application of Raman 
spectroscopy for diagnostics: conventional Raman 
microspectroscopy, Raman spectroscopy with a 
fiber-optic probe and Raman optical tweezers. A 
detailed description of each of these methods will 
be discussed in Sections 3.2, 3.3 and 3.4, respectively, 
with an emphasis on how to integrate these systems 
into a standard microscope at a minimal cost. 
 –  Section 4 reviews the various contributions on the 
application of Raman spectroscopy to bladder-
cancer diagnostics over the last decade. This starts 
by discussing the diagnostic classification algorithms 
and how the performance of these models is 
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determined using cross validation methods. Section 
4.2 summarizes all previous applications of Raman 
spectroscopy to diagnose bladder biopsy and tissue 
samples  in vitro and  ex vivo . Section 4.3 then focuses 
on the use of Raman fiber-optic probes integrated 
into cystoscopes for real-time cancer diagnostics  in 
vivo . Both of these techniques have been shown as 
being highly accurate for discriminating between 
healthy and cancerous bladder tissue, as well as 
identifying the exact stage/grade of disease present 
in a minimally invasive manner. Section 4.4 proceeds 
to describe the completely non-invasive technique of 
combining Raman spectroscopy with urine cytology. 
Here, Raman spectroscopy has been successfully 
applied to cells obtained from voided urine for 
diagnosis of bladder carcinoma with high sensitivities 
and specificities. 
 –  Finally, Section 5 demonstrates the use of Raman 
spectroscopy as an aid for investigating the etiology 
of bladder cancer. Raman spectroscopy has the ability 
to identify the biochemistry of a tissue sample, and 
has been utilized to identify the molecular changes 
associated with the biochemical continuum of disease 
as it progresses from healthy to a high-grade bladder 
carcinoma. 
2   Bladder disease and diagnosis 
2.1   Diagnosis of bladder pathology 
 The main bladder pathologies associated with this review 
are cystitis (i.e. inflammation of the bladder), bladder 
outlet obstruction, benign bladder tumors, dysplasia/
atypia (i.e. abnormal cells) and bladder cancer, which 
are generally diagnosed using cystoscopy, aided by urine 
cytology. Cystoscopy is an invasive endoscopic procedure 
of the urinary bladder carried out via the urethra, however 
it is sometimes indeterminate and there are variables that 
can result in false negative results. 
 Bladder mucosa inflammation (cystitis) is commonly 
encountered in individuals with a urinary tract infection 
and individuals with indwelling catheters, and  carcinoma 
in situ (CIS), a particularly aggressive form of non-inva-
sive bladder cancer with a high propensity to progress 
to muscle invasive disease, also appears as inflamed 
bladder lining. Cytology is useful when a high-grade car-
cinoma (HGC) or CIS is present but its use in the diagno-
sis of low-grade carcinoma (LGC) is very limited owing to 
its low level of sensitivity  [14] . As a standard procedure, 
cystoscopy is performed using white light. However, the 
use of white light can lead to missing lesions that are 
present but not visible, which is why new technologies 
are being developed. 
 Photodynamic diagnosis (fluorescence cystoscopy) 
is performed using violet light after intravesical (intra-
bladder) instillation of 5-ALA or HAL. It has been con-
firmed that fluorescence-guided biopsy and resection 
are more sensitive than conventional procedures for the 
detection of malignant tumors, particularly for CIS of the 
bladder  [15] . This paper reviews the advantages of using 
Raman spectroscopic techniques for the diagnosis of 
bladder pathologies in real-time with high sensitivities 
and specificities. 
2.2   Classification of bladder carcinoma 
 Approximately 90% of all bladder cancers are diagnosed 
as urothelial carcinoma (UC), otherwise known as tran-
sitional cell carcinoma (TCC)  [16] . UC develops in the 
urothelium of the bladder wall, and is the second most 
common malignancy of the genitourinary tract  [17] . The 
remaining  ∼ 10% of bladder cancers consist of squamous 
cell carcinoma (SCC), adenocarcinoma and small cell car-
cinoma. Almost 80% of patients with TCC present with 
non-muscle-invasive or superficial bladder cancer, the 
remainder being infiltrative, invading the detrusor muscle 
and potentially spreading to loco-regional lymph nodes 
and viscera  [18] . There are two main diagnostic classifi-
cation systems for UCs based on histological grading and 
pathological staging. Histological grading represents the 
degree of differentiation present between the carcinoma 
cells and normal urothelial cells which can be used to 
predict the rate at which the carcinoma cells are multi-
plying. Pathological staging is used to assess the extent 
of cancer invasion into the bladder wall in order to deter-
mine if the disease has spread. 
2.2.1   Histological grading 
 The histological grade of a UC tumor is determined under 
a microscope using a specific set of criteria to establish 
how much the tumor resembles normal (healthy) tissue. 
Within histological grading, there are two systems in use; 
the World Health Organization (WHO) 1973 grading system 
and the WHO 2004 grading system. Most histopatholo-
gists still use the WHO 1973 system, which is based on 
a three-tiered grading system as summarized in  Table  1 . 
Grade 1 represents well differentiated cells that are slow 
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growing and look similar to healthy bladder cells, Grade 2 
cells are moderately differentiated, and Grade 3 are poorly 
differentiated, fast growing cells that look very different to 
healthy cells  [19] , as illustrated in  Figure 1 . 
 Histological grading is often criticized given the sub-
jective nature of this test as it is based on the pathologist ’ s 
perception of cell differentiation. Generally, diagnosis is 
made by two or more pathologists per sample in order 
to avoid misclassification, however there is still often 
inter-observer variation (between pathologists) and intra-
observer variation (from one pathologist at different times) 
 [20] . Thus, this method of classification is time-consum-
ing with a high degree of variability. The future trend is 
leaning towards the use of the newer system (WHO 2004), 
which is based on simply grading cancers as low or high 
grade, thus reducing inter-observer variation. 
2.2.2   Pathological staging 
 Pathological staging is based on the tumor-node-metas-
tases (TNM) system, whereby the pathologist assesses 
the location of the tumor (T), if the cancer has spread to 
nearby lymph nodes (N) and the extent of metastases (M). 
A number is assigned to each value ranging from 1 to 4, 
where higher numbers indicate a more aggressive, inva-
sive carcinoma  [21] . The tumor (T) value, which is the most 
important value in this review, represents the location of 
the tumor with respect to the inner lining of the bladder 
 Table 1   Description of bladder cancer cells corresponding to each 
histological grade. 
Histological 
grade 
  Description of cancer cells 
GX   Unable to determine the extent of differentiation
G1/low grade   Well differentiated
G2   Moderately differentiated
G3/high grade   Poorly differentiated 
 Figure 1   Basic representation of the differences between normal 
bladder cells (A) and poorly differentiated cancer cells (B). 
wall. Stages Ta, TIS (referring to  carcinoma in situ ) and T1 
are non-muscle-invasive UCs, with Ta and TIS both con-
fined to the urothelium. Most Ta and T1 tumors are low 
grade and are less likely to become muscle-invasive. TIS 
is a flat, high-grade, non-invasive UC. Macroscopically, 
CIS can be missed at cystoscopy or be considered as an 
inflammatory lesion if not biopsied. A summary of each 
pathological stage can be seen in  Table 2 , and  Figure  2 
illustrates the extent of the growth of the tumor with 
respect to the inner bladder wall lining. 
2.3   Non-malignant bladder pathology 
 Other non-malignant pathologies that may be diagnosed 
in the urinary bladder using Raman spectroscopy include 
cystitis, damage to the bladder wall caused by bladder 
outlet obstruction, dysplasia/atypia and benign tumors. 
 Cystitis is essentially inflammation of the bladder, 
usually as a result of an infection of the urinary system but 
it is often difficult to detect using conventional methods. 
Bladder outlet obstruction, most commonly caused from 
an enlarged prostate or urethral structure, may result in 
progressive deterioration of the bladder and ultimately 
kidney function, and it is often difficult to determine the 
extent of the loss of functionality that will be present after 
surgical removal of the obstruction. Raman spectroscopy 
has the potential to improve the diagnosis of bladder 
functionality due to urethral obstruction by analysing 
the bladder wall composition. Raman spectroscopy can 
also be applied to regions of dysplasia/atypia and benign 
tissues, and be able to clearly distinguish between these 
and cancerous tissue cells. 
3   Raman spectroscopy 
3.1   Introduction to Raman spectroscopy 
 Raman spectroscopy is a powerful tool for the analysis of 
the biomolecular composition of biological samples. This 
technique is based on the inelastic scattering of mono-
chromatic (laser) light; this means that when light inter-
acts with the biological sample, the emitted photons have 
a different energy to the incident photons. Only about one 
in 10  7  photons will undergo Raman scattering  [22] , the 
rest will undergo Rayleigh scattering as normal.  Figure 3 
compares the energy differences between photons 
emitted during Rayleigh scattering and Raman scattering, 
whereby there is no change in energy between incident 
Brought to you by | National University Ireland  Maynooth
Authenticated | lauratheresekerr@gmail.com author's copy
Download Date | 5/14/14 10:58 AM
L.T. Kerr et al.: Applications of Raman spectroscopy to the urinary bladder for cancer diagnostics      5
 Table 2   Description of bladder cancer tumor corresponding to each pathological stage  [21] . 
Pathological stage   Description of tumor 
T0   No primary tumor
Ta   Non-invasive papillary tumor, confined to urothelium
TIS/CIS   High-grade, flat tumor, confined to urothelium
T1   Invasive tumor; invades lamina propria (connective tissue region)
T2   Muscle invasive tumor
  T2a  – tumor invades inner half of muscle layer
  T2b  – tumor invades outer half of muscle layer
T3   Tumor invades perivesical fat layer beyond the muscle region
  T3a  – microscopically
  T3b  – macroscopically
T4   Tumor invades nearby tissues such as the prostate, vagina, uterus, pelvic wall or abdominal wall
  T4a  – tumor invades prostate, uterus or vagina
  T4b  – tumor invades pelvic wall or abdominal wall
 TIS/CIS,  carcinoma in situ . 
Fat layer
Muscle layer
Lamina propria
Urothelium
Bladder
T4
T3
T2
T1
Ta
CIS/TIS
 Figure 2   Staging of bladder tumors representing the location of 
each tumor with respect to the urothelium. 
photons and Rayleigh scattered photons, but Raman scat-
tered photons either gain energy (Anti-Stokes) or lose 
energy (Stokes) during this scattering process. The magni-
tude of the change in energy seen in the Raman photons 
is dependent on the rotational and vibrational energies 
of the molecules in the biological sample  [23] . By analyz-
ing these Raman photons, it is possible to determine the 
molecular composition of the sample being investigated. 
Typically only Stokes photons are measured since these 
have a higher intensity than Anti-Stokes photons. By 
recording and measuring the emission of inelastic photons 
in the form of Raman spectra, it is possible to detect the 
molecular differences between normal and diseased or 
cancerous cells within a biological sample, making it an 
ideal technique for diagnostics. 
 Raman spectroscopy is suitable for use in biofluid 
analysis because water is a weak Raman scatterer. The 
peaks of the different wavelengths that are emitted are 
unique to a particular molecule and this enables finger-
print-like recognition of complex molecular combina-
tions. A Raman spectrometer can be fitted to a microscope 
so that a spectrum can be obtained from microscopic 
points in a sample, e.g., the nucleus of a cell. It has been 
shown that recording spectra from tissue and cells from 
patients with known disease, allows for the training of 
statistical classification algorithms that enables the diag-
nosis of disease from unknown samples. Various statis-
tical techniques of unsupervised and semisupervized 
clustering have been employed to analyze Raman spectral 
alterations in disease conditions, and have been so far 
impressively successful in differentiating normal versus 
cancerous tissue. 
 There are various techniques used for applying 
Raman spectroscopy to biological samples. Most often, 
conventional Raman microspectroscopy is applied for the 
interrogation of biological material, but other techniques 
such as the use of a fiber-optic probe (for  in vivo applica-
tions), Raman tweezers  – i.e., the application of Raman 
spectroscopy in a laser tweezers set-up, Raman mapping 
 – i.e., where a two-dimensional (2-D) Raman spectro-
scopic grid is generated of the tissue area which provides 
biochemical images and Kerr-gated Raman spectroscopy 
(for tissue depth profiling), have been used for analyzing 
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the urinary bladder. Further details of the set-up for each 
method will be discussed in Sections 4.3 and 4.4. 
 Raman spectroscopy provides many advantages over 
other diagnostic techniques; it is fast, giving accurate 
diagnostic results in real time, but there are also limita-
tions to this technique that need to be considered. Strong 
background signals are often detected which overlap 
with the Raman signal, making it difficult to distinguish 
which signals are associated with the biological sample. 
A variety of pre-processing statistical techniques have 
been applied to date to remove this noise, and a range of 
substrates and laser wavelengths have also been used to 
minimize background signals. 
 Good substrates for Raman spectroscopy should be 
transparent in the visible/near-infrared (NIR) region, 
produce a low background signal, and should be bio-
compatible and non-toxic for the cells or tissues placed 
on them. For example, glass in particular is known to 
produce a large background signal when used in conjunc-
tion with a NIR laser source, so the use of other optically 
transparent substrates such as calcium fluoride (CaF 2 ) 
and quartz are preferred for Raman spectroscopy in the 
NIR. A more detailed discussion on pre-processing is 
given in Section 3.5. 
 A basic Raman spectroscopic set-up must consist of 
four main components: (i) an excitation source, i.e. laser, 
(ii) an optical system to deliver the light to the sample with 
minimum power loss, (iii) a collection system with highly 
efficient optics that can collect an optimum amount of 
Raman scattered light whilst being able to remove all Ray-
leigh signals, and (iv) a detection system, i.e. spectrograph 
and charge-coupled device (CCD). A basic design of this 
optical method is shown in  Figure 4 , where additional 
Raman scattering:
Stokes Anti-stokes
Stokes lines
Wave number (cm-1)
Rayleigh line
E=hcv –ΔE
In
te
ns
ity
~
~
Anti-stokes lines
E=hcv+ΔE~
E=hcv 
Rayleigh
scattering
A B
Virtual
energy
states
Vibrational
energy
states
0
1
2
~E=hcv ~E=hcv ~E=hcv ±ΔE
 Figure 3   (A) Energy level diagram for incident photons, and photons emitted during Rayleigh scattering and Raman scattering. 
(B) Emission lines for Rayleigh scattered photons and Raman scattered photons. ( E = energy,  h = Planck ’ s constant,  c = speed of light, 
 v = wavenumber of the photon,  Δ E = change in energy). 
Laser
beamSample
Optical
system
Pinhole aperture
Spectrograph
Cooled
CCD
Laser
 Figure 4   Basic set-up used for Raman spectroscopy. 
optical elements can be inserted to optimize the system. 
There are many advantages to using lasers from the NIR 
range in the use of Raman spectroscopy for biological analy-
sis; it allows for exploitation of the optical window which 
results in greater scattering within the biological sample, 
thus producing a larger Raman signal, whilst maintaining 
low levels of biological damage. Since the scattered Raman 
signal is very weak relative to the laser source beam, it is 
important to have efficient optical systems for both deliv-
ering the laser beam directly to the sample with sufficient 
power and for collecting the scattered Raman photons. To 
achieve this, a series of mirrors and lenses are used to direct 
the optical path directly to where it is needed, and filters 
are used to remove unwanted signals. It is also possible to 
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include a pinhole aperture to isolate the spectrum from a 
particular location in the sample, the effect of which is to 
greatly reduce the background signal and to enable point-to-
point spectral mapping. The detection system consists of a 
spectrograph and a CCD detector. Thermal energy can often 
generate noise and dark current on the CCD which can block 
out the distinct Raman peaks. To avoid this, and to maintain 
a good signal-to-noise ratio (S/N), the CCD must be cooled. 
3.2   Conventional Raman microspectroscopy 
 Conventional Raman microspectroscopy, involves the 
use of a microscope and a confocal aperture in order to 
isolate the Raman spectrum from a specific microscopic 
three-dimensional (3-D) point in a specimen and has been 
applied to both bladder tissue and cells for analysis and 
classification. The laser beam can be delivered at 180 ° 
to the sample surface or at 90 ° , in either a reflection- or 
transmission-based system. Biological samples can be 
measured both  in vitro and  ex vivo with this method by 
mounting them onto a substrate. A Raman spectrometer 
can be fitted to an existing microscope so that a spectrum 
can be obtained from microscopic points in a sample, e.g., 
the nucleus of a cell, and this has been the basis of much 
work in bladder cancer diagnostics.  Figure 5 illustrates the 
Raman microspectrometer that has been custom built in 
our lab for experiments in bladder cancer diagnosis. This 
basic design can be found in most commercial Raman 
microspectrometers from long established companies 
such as Renishaw and Horiba Raman. A state of the art 
Raman microscope will cost in the order of  $ 100,000 but 
an equivalent one can be built from basic elements for less 
than half this amount. 
 The design in our lab is as follows; a laser with a 
narrow bandwidth (Sacher Lasertechnik, Germany; TEC 
520 7080 – 100, wavelength 785 nm, power 120 mW) is first 
passed through an optical isolator  OI (Sacher Lasertech-
nik, Germany; ISO – 35 – 0780) which prevents back reflec-
tions from the set-up from returning into the laser cavity 
and thereby damaging the laser head. This is followed by 
a line pass filter  LP (Semrock Inc., NY, USA; LL01 785 – 12.5) 
which removes any spurious lines from the laser that 
may result from additional modes being present. Only 
the line at 785 nm is allowed to reach the neutral density 
filter  ND (Edmund Optics Inc., NJ, USA) which can be 
rotated in order to vary the power of the laser beam that 
is allowed to pass through it. Two lenses,  L1 and  L2 (Thor-
labs, Germany), are used to expand the laser beam such 
that the diameter of the collimated beam is approximately 
equal to the back aperture of the microscope objective 
 MO (Olympus, Japan; 50 × , numerical aperture NA = 0.85, 
UMPlanFl) which will be discussed shortly. 
 A system of two mirrors  M is used to direct the col-
limated beam onto a dichroic beam splitter  DB (Semrock 
Inc., NY, USA; LPD01 – 785RS) which will reflect light at 
785  nm but transmit other wavelengths. The dichroic 
beam splitter reflects the beam towards a hot mirror  HM 
(Edmund Optics Inc., NJ, USA), which is another form of 
dichroic beam splitter, in this case reflecting all wave-
lengths above 650 nm and transmitting all shorter wave-
lengths. The hot mirror is located within the fluorescence 
cube cavity of an inverted Nikon phase contrast micro-
scope (Nikon, Toyko, Japan; Diaphot 300) and is carefully 
aligned such that it reflects the beam directly into the back 
of the microscope objective. The microscope objective is 
chosen such that it has a high numerical aperture which is 
essential to recover as many Raman backscattered photons 
 Figure 5   Schematic of a conventional Raman spectroscopy set-up. 
 OI, optical isolator; LP, line pass filter; ND, neutral density filter; L1 and L2, lenses; M, mirrors; DB, dichroic beam splitter; MO, microscope 
objective; HM, hot mirror; S, sample; TS, translation stage; HN, holographic notch filter; L3, lens; CA, confocal aperture; L4, lens; LP, long 
pass filter; SL, entrance slit; CM, collimating mirror; DG, diffraction grating; FM, focusing mirror; CCCD, cooled CCD camera; HL, halogen 
lamp; F, green filter; C, condenser; SP, short pass filter; DC, digital camera. 
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as possible. It is also essential that the microscope objec-
tive efficiently transmits light in the NIR as this will also 
impact on the system to recover a strong Raman signal. 
Plan fluorite microscope objectives provide satisfactory 
performance. The microscope objective focuses the beam 
to a diffraction limited spot on the sample  S . The sample is 
placed on a translation stage  TS (Applied Scientific Instru-
mentation, OR, USA; LS – 2000 and LS – 50) that enables 
sample positioning relative to the laser spot. In the case 
of Raman diagnostics, it is desirable to position the cell 
such that the spot is located within the cell nucleus as this 
results in optimum diagnostic sensitivity. 
 The backscattered Raman photons (785 – 1100  nm) 
travel back through the microscope objective and are 
reflected by the hot mirror and then pass through 
the dichroic beam splitter. A holographic notch 
filter  HN (Kaiser Optical Systems Inc., MI, USA; 
HNF – 785.0 – 1.0) serves to remove light at 785 nm that has 
made its way through the dichroic beam splitter, and to 
transmit all other wavelengths. Following this a third 
lens  L3 (Thorlabs, Germany) focuses the light to a 100  μ m 
confocal aperture  CA (Thorlabs, Germany). The presence 
of the confocal aperture ensures that light reaching the 
spectrograph has originated from a 3-D volume within 
the object in the order of 1  μ m in all three dimensions. 
This allows for 3-D localization of the Raman signal from 
the sample. A further lens  L4 (Thorlabs, Germany) forms 
a one-lens imaging system from the confocal aperture to 
the entrance slit  SL of the spectrograph (Andor Technol-
ogy, Belfast, UK; Shamrock 500). A long pass filter  LP 
(Semrock Inc., NY, USA; LP02 – 785RU – 25) is placed near 
the entrance slit in order to further reduce any Rayleigh 
scattered/laser light that has reached the spectrograph. 
Via a collimating mirror  CM , a diffraction grating  DG , 
and a focusing mirror  FM , the image of the slit is pro-
jected onto a cooled CCD camera  CCCD (Andor Technol-
ogy, Belfast, UK; DU420A – BR – DD), where each row of 
pixels records an image of the slit corresponding to a 
specific wavelength, and in this way the Raman spectrum 
is recorded using the Andor Solis software system. It is 
essential to use a high quantum-efficiency, low-noise, 
cooled CCD in order to recover the weak Raman signal 
with minimal noise. 
 Independently, light from the 100-W halogen lamp  HL 
(Nikon, Japan) at the top of the inverted microscope passes 
through a green filter  F (Nikon, Japan) and then through an 
Abbe condenser  C (Nikon, Japan) which focuses the light 
onto the sample and into the microscope objective. Since 
the green light has a shorter wavelength than 650 nm, 
the light passes through the hot mirror and then through 
the short pass filter  SP (Semrock Inc., NY, USA; FF01 – 775/
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 Figure 6   (A) An image of a fixed bladder cancer cell (T24, American 
Type Culture Collection) recorded on the digital camera, and (B) the 
Raman spectrum recorded on the cooled CCD corresponding to the 
point indicated in (A). 
SP – 25), which is designed to transmit all wavelengths 
shorter than 775 nm and block higher wavelengths. This 
has the effect of preventing any further transmission 
of Rayleigh light that has managed to pass through the 
holographic notch filter. The green light passes into the 
body of the microscope where it reflects from an internal 
mirror through an internal imaging system, and images 
onto a digital camera  DC (Basler, Ahrensburg, Germany; 
acA2000 – 340 km) fixed to the front exit port of the micro-
scope.  Figure 6 A shows an image of bladder cancer cells 
recorded on the digital camera, and Figure 6B the Raman 
spectrum recorded on the cooled CCD corresponding 
to the point indicated in Figure 6A. It is of note, that the 
wavenumbers (cm -1 ) used on the axis can be converted 
into wavelength (nm). 
 To perform a diagnostic measurement, spectra are 
recorded from multiple cells from each patient sample. 
Using a set of known samples, the spectra are grouped 
into categories according to pathological information 
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obtained from a consultant histopathologist. Application 
of the dimension reduction method of principal compo-
nents analysis (PCA) enables training of a classification 
algorithm in order to identify the presence (and grade) 
of TCC, and the sensitivity/specificity of the approach 
is often determined using a cross validation method. A 
more detailed discussion of Raman-based diagnostics is 
given in Section 4. Another related approach is Raman 
mapping where the translation stage is scanned in three 
dimensions and sequential confocal Raman spectra are 
recorded. Statistical clustering approaches can be used to 
group points that share a similar biochemistry and these 
regions can be represented with pixels of the same color. 
Raman mapping is discussed in Section 5. 
3.3   Raman spectroscopy with a 
fiber-optic probe 
 A fiber-optic Raman spectroscopy set-up consists of a 
specialized fiber probe, an excitation source (laser), 
fiber couplers to deliver the light in and out of the fiber, 
filters to remove unwanted signals and a detection system 
(spectrograph and cooled CCD camera), as can be seen 
in  Figure 7 . This fiber-optic probe can be inserted during 
a cystoscopy procedure, and be used to give real-time 
analysis and classifications of the urothelium. Similar 
to conventional Raman microspectroscopy, the Raman 
fiber-optic probe can be used to monitor  in vitro and  ex 
vivo specimen also. The main advantages of this system is 
the potential to replace the need for multiple biopsies, a 
reduction in the turn-around time for diagnosis, a reduc-
tion in histological/pathological costs and an improved 
surgical procedure by using the probe to identify border 
regions of diseased or damaged tissue. 
 A Raman probe for cystoscopic or endoscopic diag-
nostics must be able to fit into the instrument channel of 
a standard cystoscope (or endoscope or catheter), be bio-
compatible and robust enough to withstand decontami-
nation/disinfection processes. NIR lasers (785 – 830 nm) 
are generally used for Raman fiber-optic probes because 
they minimize thermal damage to the tissue sample being 
analyzed. It is also essential that there is a low Raman 
signal generated within the probe. The general design of a 
Raman fiber-optic probe is shown in Figure 7; consisting of 
a central delivery fiber which is surrounded by several col-
lection fibers, where the diameter of each fiber is between 
100 and 400  μ m depending on the system design. Typi-
cally a bandpass filter is placed at the tip of the excita-
tion fiber to remove unwanted background signals, and a 
longpass filter is placed at the tip of the collection fibers to 
prevent Rayleigh scattered light from entering these fibers. 
Lenses (such as a ball lens, made from sapphire) at the 
probe tip or tapered fiber tips can also be used to improve 
the efficiency of delivering both the excitation light to the 
tissue and Raman scattered light into the collection fibers 
(further information is available in  [24] ). 
 Commercially available Raman probes have been 
applied to the urinary bladder for diagnostics, such as the 
Enviva Biomedical Raman Probe (Visionex Inc., Atlanta, 
GA, USA) and the Emvision Raman probe (Emvision, 
LLC, Loxahatchee, FL, USA). Many homemade Raman 
probes have also been designed that could be integrated 
into  in vivo bladder studies. An optical multi-fiber cath-
eter was designed by de Lima et al.  [25] , with greater effi-
ciency, lower background signals and greater flexibility 
Filter
Coupler
Fiber optic
probe
Coupler Lens
Filter
Grating
Sample Cooled CCD
Spectrograph
Laser
 Figure 7   Schematic of the Raman fiber-optic probe set-up, which can be applied to biological samples both  in vivo and  in vitro , with a front 
view of the design of a fiber-optic probe inset, showing the central delivery fiber which is surrounded by several collection fibers. It is of 
note that it is often more conventional to integrate the filters into the tip of the fiber-optic probe instead, but for ease of illustration, they 
have been shown in the positions above. 
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than many other fiber probes. This was achieved by 
using a low NA (0.12) excitation fiber and a higher NA 
(0.22) collection fiber, and replacing the standard silver 
epoxy resin adhesive and transparent tube found on 
catheters with a black epoxy resin adhesive and a black 
Teflon tube covering. A confocal Raman probe was 
recently constructed by Barman et al.  [9] by introducing 
a 150  μ m pinhole aperture into the system at the proxi-
mal end of the fiber probe, which the authors stated to 
provide higher specificity than a standard Raman probe. 
In another recent study, a subcutaneous Raman needle 
probe was designed by Day et al.  [26] incorporated a min-
iature fiber probe into a standard hypodermic needle; 
this was achieved by using only two fibers, one for exci-
tation and one for collection, with laser power of 24 mW 
reaching the tissue sample and an acquisition time of 
30 s for each measurement. 
 One of the main problems associated with Raman 
fiber-optic probes is that the fused silica from the fiber 
generates a Raman signal which can block out the signals 
from the biological sample. This can be reduced using low 
OH fibers. An alternative option, suggested by Koljenovi ć 
et al.  [27] , is to record spectra from the high wavenumber 
range (2400 – 3800 cm -1 ) where there is no Raman signal 
from the silica fiber. However, the fingerprint region 
(400 – 1800 cm -1 ) is typically used for analyzing biological 
specimen since this is where the optimum Raman signals 
are collected. It is of note, that Praveen et  al.  [28] were 
recently able to reduce fluorescent background signals 
by integrating a modulated NIR laser into the fiber-optic 
Raman system. Other difficulties with Raman probes are 
the long acquisition times needed, poor S/N, the lack of 
wide-field measurement capabilities, and complications 
with designing a probe which can withstand everyday 
usage in a clinical environment  [6] . 
 A potential further development for Raman fiber-optic 
probes for diagnostics is based on photonic crystal fibers 
since there are many advantages to using these instead of 
silica fibers. Photonic crystal fibers are hollow, and there-
fore don ’ t add any contributions to the Raman signals col-
lected  [29] . It is also possible to use one photonic crystal 
fiber for both excitation and collection, thus overcoming 
the technical challenge of packing several fibers into a 
small probe. 
3.4   Raman optical tweezers 
 A Raman tweezers is based on combining the principle of 
Raman microspectroscopy as described previously and 
optical trapping (or laser tweezing)  [30, 31] . The latter is 
a technique that utilizes a high NA microscope objective, 
usually configured in an inverted microscope, together 
with a suitable laser, to trap a cell in the waist of a focused 
laser beam. The tightly focused light creates a sharp gradi-
ent of intensity which leads to gradient forces trapping the 
cell. The trapped cell can be suspended in a liquid (or air) 
environment and moved in three dimensions by manipu-
lating a component in the optical set-up. By combining 
Raman microspectroscopy with optical trapping, individ-
ual cells can be biochemically probed under physiological 
conditions or in microfluidic chips. 
 There are at least two separate physical models that 
describe optical trapping. The first of these is based on 
Mie scattering, i.e., on the condition that the trapped par-
ticle has a diameter that is significantly greater than the 
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 Figure 8   Schematic of a standard Raman optical tweezers set-up (A) and a dual beam Raman tweezers set-up (B). 
 HL, halogen lamp; C, condenser; MO, microscope objective; HM, hot mirror or more accurately a suitably flat dichroic mirror; DC, digital 
camera; L, lenses; M, mirror; DB ’ and DB, dichroic beam splitter; HN, holographic notch filter; CA, confocal aperture; LP, long pass filter; 
CCCD, cooled CCD camera. 
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wavelength of the light. In this model basic ray optics can 
be used to determine the gradient optical forces acting 
on the particle. An illustration of this model is shown in 
 Figure 8 A. Here two rays of light can be seen intersect-
ing at the focal point of the microscope objective. At the 
surface of a sphere they are refracted due to a difference in 
the refractive indices of the chamber fluid and the sphere. 
This refraction brings about a change in momentum of the 
light rays, which according to Newton ’ s third law must be 
transferred to the sphere, illustrated by the thick black 
arrows in the figure. The resultant forces on the sphere 
act to trap the particle in a static position in the horizontal 
plane, while the sum of their components in the vertical 
direction force the particle back towards the focal point. In 
addition to the gradient office there is a second force acting 
on the particle known as the scattering component which 
can be described as a  “ fire hose ” pushing the sphere away 
from the microscope objective in the direction of propa-
gation  [31] . So long as the gradient force is greater than 
the scattering force, the sphere comes to rest at a point of 
equilibrium, slightly  “ downwind ” of the lens ’ focal point, 
where all of the forces cancel. In instances where this is 
not accomplished a second counter-propagating trap can 
be implemented using a second microscope objective  [32] . 
 The second physical model that describes optical trap-
ping is based on Rayleigh scattering where the particles 
are significantly smaller than the wavelength of the light, 
which is derived using the theory of electromagnetics. For 
cellular analysis, where the cell size is approximately 5 – 10 
times that of the wavelength, trapping operates some-
where in between the two models. Regardless of which 
model is valid, the strength of the trap is proportional to 
the laser power and so high-power lasers are preferable, 
which necessitates longer wavelengths (e.g. 1064 nm) 
to minimize photobleaching and cell damage. Another 
important property is the laser beam profile, which 
should have a clean Gaussian shape (known as a TEM00 
spatial mode). This property ensures the narrowest possi-
ble focus and balanced trapping forces acting on all sides 
of the cell. Other desirable properties include good point-
ing stability and low power fluctuation. 
 A typical set-up for optical trapping is shown in 
Figure 8A. A laser is expanded using two lenses  L1 and  L2 
which should provide sufficient magnification such that the 
laser beam is expanded to have a diameter approximately 
equal to the aperture at the back of microscope objective  MO ; 
ideally the 1/e 2 intensity points on the beam profile should 
match the aperture which ensures that 87% of the energy 
will enter the objective. The expanded laser beam then 
passes through two identical lenses,  LA and  LB , which are 
separated by a distance equal to twice their focal length. The 
purpose of these two lenses is to provide a means of moving 
the focal point of the trap in the x, y and z dimensions. 
 The distances in the set-up should be arranged such 
that  LB forms a one-lens imaging system between the 
plane of  LA and the back of the microscope objective (both 
planes are marked with dashed lines in the figure). This 
property ensures that if the lens,  LA , is physically moved 
horizontally and vertically the beam will still target the 
microscope objective aperture exactly, while the angle of 
the beam will change resulting in a shift of the position of 
the trap. The microscope objective must have a sufficiently 
high NA ( > 1.25) to create a gradient that is capable of trap-
ping and so oil immersion objectives are usually used. It 
must also have high quality aberration compensation to 
create a tightly focused trap. Located between the lens  LB 
and the microscope objective is a dichroic beam splitter of 
some variety, similar to the previous hot mirror  HM , but 
with sufficient surface flatness to ensure the laser beam is 
unaffected, which reflects the trapping laser while allow-
ing the shorter wavelength light from a halogen lamp  HL 
pass through unaffected. Light from the halogen lamp 
illuminates the sample via a condenser lens  C and forms a 
magnified image on a digital camera  DC so that the trapped 
particle can be observed. The trap can be moved in three 
dimensions by moving the lens  LA correspondingly. The 
trapped particles are usually contained in liquid within a 
glass chamber, the base of which has a thickness equal to 
that of a standard coverslip (170  μ m). A more detailed dis-
cussion of optical trap design can be found in  [31] . 
 A direct comparison of the Raman microspectroscopy 
set-up shown in Figure 5 (not considering the elements 
to the right side of the dichroic beam splitter  DB ) and the 
optical tweezers set-up shown in Figure 8A leads to the 
conclusion that both systems have similar characteristics. 
It is clear that the Raman system is effectively the same as 
the tweezers system except for the presence of lenses  LA 
and  LB . These could easily be included or left out if trap 
movement is not needed. Therefore, by ensuring that the 
laser and the microscope objective have the properties nec-
essary for trapping as discussed above, then the Raman 
microspectroscopy system can also serve as an optical trap. 
 Interestingly, it has been shown that cells trapped 
in such a system are trapped by the nucleus  [33] and this 
ensures that the Raman signal measured essentially ema-
nates from the nucleus of the cell which is advantageous 
for diagnostic classification. In such a case it may be pos-
sible to remove the confocal aperture in the system and 
thereby increase the power in the Raman signal by obtain-
ing an average spectrum from the entire nucleus. 
 Another compromise is to use a dual beam Raman 
tweezers such as that described in  [34] . Such a system, 
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as illustrated in Figure 8B combines the optical trap in 
Figure 8A and the Raman microspectrometer in Figure 
5. In this case two lasers are employed: one for Raman 
excitation (expanded using  L1 and  L2 ) and one for trap-
ping (expanded using  L1 ′ and  L2 ′ ). The only element 
that was not already introduced is the dichroic beam-
splitter,  DB ′ , which reflects the 1064 nm wavelength but 
transmits all others. It is of note, that for the sake of 
brevity some of the optical elements shown in Figure 5 
were omitted. 
 There are a number of advantages to such a decou-
pled system; firstly it allows for the use of a 1064 nm laser 
to trap the cell thereby minimizing cell damage, and facili-
tating lower wavelengths to be used for Raman excitation. 
Secondly, it allows for probing of different regions in the 
trapped cell for isolated confocal Raman spectra. This can 
be achieved by moving the trap in 3-D around the confocal 
spot of the Raman microspectrometer. 
 Raman tweezers offer exciting new avenues of 
research, particularly in the areas of microfluidics and 
urine cytology. This technique can be used for investigat-
ing the biochemistry of living cells in their natural envi-
ronment with 3-D spatial resolution  [33] . It can also be 
used for diagnostic classification for bladder cells. Both 
bladder and prostate cells have been investigated in this 
way in the literature  [32, 35 – 37] and some of the details of 
this research is discussed later in Section 4.4. 
3.5   Pre-processing of Raman spectra 
 Each Raman spectrum consists of three main components: 
Raman signals, the baseline and noise. The presence of 
these unwanted background/baseline signals and noise 
is often reduced using pre-processing techniques before 
the classification process as they can lead to a larger diag-
nostic error otherwise. Numerous techniques have been 
applied to achieve this:
 –  Wavenumber calibration: Small changes in the optical 
set-up, and/or a change in temperature can result in a 
shift in the Raman spectrum along the wavenumber 
axis. Accurate calibration is therefore required to allow 
for comparison of Raman data obtained from different 
Raman spectroscopic set-ups. This is particularly 
important when creating standard medical diagnostic 
databases for disease identification. The purpose 
of wavenumber calibration is to assign a particular 
wavenumber shift to each row of pixels in the cooled 
CCD camera  [38] . To perform wavenumber calibration 
on a Raman spectroscopic set-up, a known sample 
such as silicon is measured, and the positions 
obtained using the Raman system are calibrated with 
the precisely known Raman peak positions for the 
calibration sample used. 
 –  Baseline correction: The baseline of a spectrum is 
described as the slowly varying curve seen in the 
lower range of the spectrum without the distinct 
Raman peaks. This baseline can be varying or 
sloped, and is usually due to unwanted background 
signals or fluorescence. To remove this background 
contribution, baseline correction is performed by 
subtracting a linear or polynomial fit of the baseline 
from the original spectrum. Alternatively, the 
background signal can be recorded independently 
and subtracted from the cell/tissue spectrum. 
However this can be difficult as the overall intensity 
can vary significantly between captures. Further 
information about baseline correction choices can be 
found elsewhere  [39] . 
 –  Normalization: Normalization in the intensity axis 
is performed to adjust peak intensity values from 
each spectrum in order to provide a common scale 
for comparing Raman peaks across a range of 
spectra. Normalization is achieved by dividing each 
variable in a spectrum by some constant. There are 
two main methods of obtaining this constant value 
depending on whether peak normalization or vector 
normalization is being used. For peak normalization, 
the constant is measured as the height difference 
between the baseline and the maximum point of 
a chosen peak. Vector normalization obtains the 
constant value by calculating the sum of the intensity 
values for each variable in the spectrum, and finding 
the square root of this value  [40] . 
 –  Extended multiplicative scatter correction : This is a 
model-based method for separating physical and 
chemical variances within spectra, as explained 
elsewhere  [40, 41] . This method has the ability to 
separate Raman-scattered signals from background 
chemical absorbance signals. This method of 
pre-processing allows for better interpretation of 
Raman spectra since background chemical signals 
are removed and only Raman-scattered signals 
remain. 
 –  Wavelength modulation: Modulated Raman 
spectroscopy can be used to extract Raman signals 
from the background. This is achieved by modulating 
the excitation wavelength which results in a shift of 
the Raman signals while the unwanted fluorescence 
background remains static. By applying statistical 
methods such as PCA it is possible to obtain spectra 
which are free from background contributions  [13, 42] . 
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4   Cancer diagnostics using Raman 
spectroscopy 
 In the last 10 years, there has been growing interest into 
the diagnostic potential of Raman spectroscopy for clas-
sifying healthy and cancerous bladder tissue, as well as 
identifying the grade (or stage) of cancer present. This 
approach generally involves the training of a statistical 
algorithm based on known pathological samples, and as 
such, some degree of human error is introduced into the 
method from the beginning. Nonetheless, Raman-based 
bladder diagnostics has shown increasingly impres-
sive results, and the latest studies have demonstrated 
the potential of  in vivo real-time clinical diagnosis using 
a fiber-optic probe. It has also been shown that Raman 
spectroscopy can be utilized for diagnosing cells obtained 
from voided urine, thus becoming a completely non-inva-
sive method of accurately detecting bladder cancer. In this 
section, the progression in the area over the past 10 years 
is reviewed and the sensitivities and specificities that have 
been achieved to date under various experimental set-
tings are highlighted. 
4.1   Diagnostic algorithms 
 To identify the pathology associated with each set of 
Raman data, the spectra obtained are initially subjected 
to pre-processing methods before undergoing further 
multivariate statistical analysis. This section provides 
information on the different multivariate techniques that 
have been used to develop diagnostic algorithms for clas-
sification of data obtained from Raman spectroscopy. 
Techniques such as PCA and linear discriminant analy-
sis (LDA) are most commonly employed for classification 
of bladder disease, but other techniques have also been 
demonstrated which will be further explained as follows:
 –  Principal components analysis: PCA is a powerful 
statistical tool used to reduce the number of variables 
within a data set. To do this, PCA transforms the 
spectral data into a set of variables called principal 
components (PCs), whereby all PCs are orthogonal 
to each other and they are generated in such a way 
as to represent as much variance within the dataset 
as possible. Computationally, PCs are found by 
determining the covariance matrix of the data set, 
and calculating the eigenvectors and eigenvalues 
of this covariance matrix. The first PC is the linear 
combination of the variables and the eigenvector 
corresponding to the largest eigenvalue. The 
eigenvector with the second largest eigenvalue is used 
to construct the second PC, and so on. Thus, further PCs 
are orthogonal to the previous ones, whilst describing 
the maximum variance remaining in the data. By 
leaving out PCs with corresponding eigenvalues that 
are close to zero, it is possible to significantly reduce 
the dimensionality of the data whilst maintaining 
almost all of the spectral information; for example, 
in an average Raman spectral measurement data is 
collected between 400 – 1800 cm -1 , with measurements 
taken approximately every 10 cm -1 , thus providing 
 ∼ 140 variables in the original data set, which can be 
reduced to  ∼ 10 using PCA. Further analysis can then 
be applied to these PCs to organize them into groups, 
or clusters, representing different tissue pathologies; 
techniques such as linear discriminant analysis (LDA) 
or logistic regression analysis (LRA) are often utilized. 
The main advantage of this tool is that it provides a 
simpler representation of the data and allows for 
faster classification algorithms to be designed. 
 –  Linear discriminant analysis: LDA, also known 
as Fisher ’ s discriminant analysis, is a supervised 
multivariate technique used to optimize class 
separability by finding the direction that provides 
the best separation for two or more groups of data. 
LDA is often applied to PC scores to further reduce 
the dimensionality of the data set. This is achieved by 
finding a linear combination of vectors that maximize 
the ratio of between-group variance and within-group 
variance  [38] . By maximizing this ratio, LDA is able to 
provide the optimum separation for each group, thus 
improving classification results. 
 –  Cluster analysis: Cluster analysis refers to 
unsupervised statistical techniques used to organize 
the spectra into clusters sharing similar biochemistry. 
Most clustering methods are based on finding 
distances between and within each cluster. An average 
spectrum can be used to represent each cluster and 
these cluster averaged spectra (CAS) can be further 
classified into distinct groups such as cancerous 
or non-cancerous. For supervised classification 
methods, such as LDA or LRA, the group membership 
of all the spectra is known and this information is 
used to help reveal the structure of the data which 
then allows the classification of future observations. 
For unsupervised methods, such as hierarchical 
cluster analysis (HCA) or K-means clustering, the 
class membership is unknown and the aim is to group 
similar observations together. Cluster analysis can 
be applied to the spectral data set of a Raman map 
transformed by PCA. This allows for each grid element 
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of the Raman map to be assigned to a cluster of tissue 
area with similar molecular composition. 
 –  Cross validation : Cross validation is often used to 
estimate how accurately the diagnostic model will 
perform. This is achieved by assessing the results of 
the statistical algorithm when applied to a validation 
set of data. The most common method used for 
assessing Raman spectra models is leave-one-out 
cross validation. Leave-one-out is based on using 
a single spectrum as the validation set, and the 
remaining spectra are used as the training set for the 
algorithm. This is repeated to test each spectrum in the 
dataset, and can be used to determine how accurate 
the model is at predicting the pathological status of 
the sample. Blind testing and double blind testing 
can also be applied, these are based on concealing 
pathological information from the data in order to 
remove observer bias. 
4.2   Application of Raman spectroscopy to 
bladder biopsy/tissue samples 
 In this section the specific studies relating to the applica-
tion of Raman spectroscopy to biopsy and tissue samples 
for the purpose of bladder disease diagnosis are reviewed. 
This paper attempts to extrapolate the best practice in 
terms of the methods and tools used. This section begins 
by discussing the sources of tissue and the manner in 
which they can be stored and prepared for Raman spec-
troscopic analysis. This is followed by a review of each of 
the major studies in the area, the techniques used and the 
resulting sensitivities and specificities that were achieved. 
 To diagnose bladder tissue using conventional Raman 
spectroscopy, tissue samples can be removed from tumor-
ous regions during transurethral resection surgical proce-
dures, such as transurethral resection of bladder tumor 
(TURBT) or transurethral resection of the prostate (TURP). 
Both of these are minimally invasive surgical procedures, 
carried out via the urethra by passing surgical tools 
through a cystoscope into the bladder. Large tumors or CIS 
are more difficult to remove or analyze during TURBT or 
TURP, so biopsy samples can be taken during cystoscopy 
procedures instead. A more invasive surgical procedure 
for the removal of all or part of the bladder is known as 
a cystectomy, and these tissue samples can also be diag-
nosed using Raman spectroscopy. 
 Raman spectroscopy can be effectively applied to both 
fresh and preserved bladder tissue samples. There are 
numerous methods of preserving bladder tissues so that 
they can be stored for long periods of time without largely 
affecting their natural biochemistry. Tissue samples can 
be snap-frozen with liquid nitrogen upon removal from 
the patient, and then stored at  – 80 ° C. The main advan-
tage with freezing is that the biochemistry of the samples 
are not altered and they can be analyzed simply by return-
ing the samples to room temperature. Bladder tissue could 
also be stored in paraffin-wax blocks; however it is more 
difficult to analyze tissue samples that have been stored in 
paraffin with Raman spectroscopy since paraffin has large 
distinct peaks that appear in the Raman spectra. Despite 
this, it is possible to restore the tissue to a usable state 
with the use of particular deparaffinization techniques. 
 Prior to  in vitro / ex vivo Raman spectral measurements, 
bladder tissue samples should be brought to room temper-
ature, cut into thin sections (generally  < 50  μ m thick) and 
placed onto a substrate such as CaF 2 , aluminum or quartz. 
Similarly, biopsy samples should be placed directly on to 
the substrate at room temperature. 
 These tissue samples are then inserted to the Raman 
set-up for measurement and analysis.  Table 3 shows the 
Raman capturing methods, laser details, substrates used 
and the wavenumber range recorded in publications 
that have used conventional Raman microspectroscopy 
to diagnose and grade bladder cancer tissue and biopsy 
samples. 
 In 2002, in what is believed to be the first Raman-
based bladder cancer diagnostic study, Stone et  al.  [43] 
investigated the combined use of conventional Raman 
spectroscopy with a diagnostic algorithm to classify or 
 Table 3   Capture method, substrates and wavelengths used for Raman spectroscopy based diagnostic model for diseases associated with 
bladder tissue. 
References   Year   Raman optical 
method 
  Laser 
wavelength (nm) 
  Laser power [at 
sample] (mW) 
  Substrate (if 
applicable) 
  Wavenumber 
range (cm -1 ) 
 [43]   2002  Conventional   830  85  Calcium fluoride   400 – 1800
 [44]   2004  Conventional   830  300  NS   300 – 1800 a 
 [45]   2006  Mapping   845  100  Calcium fluoride   400 – 1800
 [11]   2009   Conventional   830   300 [100]   Calcium fluoride   NS 
 a Exact wavenumber range not given, assumption made from Raman spectra provided; NS, not specified. 
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distinguish between different pathological grades of 
bladder epithelial tissue. Bladder tissue samples were col-
lected during cystoscopy procedures from 12 patients, and 
classified as being normal, CIS, LGC, medium-grade car-
cinoma (MGC) and HGC by histopathologists. At least 15 
Raman spectra were obtained from each sample, with an 
integration time of 10 s per spectrum. Spectra were then 
put into a multivariate analysis consisting of PCA, LDA 
and leave-one-out cross validation, which separated the 
spectra into five distinct groups with sensitivities between 
78% and 98% and specificities between 96% and 99%. 
Further breakdown of these results can be seen in  Table 4 . 
These results show excellent group separation, however 
some overlap is found between CIS and LGC, and between 
MGC and HGC which the author notes is either due to 
the biochemical continuum of disease or from difficulty 
in distinguishing between pathological groups during 
histopathological classification. Nonetheless, this paper 
clearly demonstrates the potential of Raman-based classi-
fication for improving the diagnosis of bladder pathology. 
 Members of the previous study further developed this 
diagnostic model using Raman spectroscopy to distin-
guish between a larger range of bladder tissue patholo-
gies  in vitro and to grade and stage TCC  [44] . Conventional 
Raman spectroscopy was applied to a range of bladder 
tissue pathologies (normal, cystitis, CIS, G1 TCC, G2 TCC, 
G3 TCC, G3 squamous dysplasia and adenocarcinoma). 
These tissues were obtained from 72 patients during 
TURBT, TURP and cystectomy procedures, and samples 
were classified by a consultant uropathologist and a 
consultant pathologist. All tissues were snap-frozen and 
stored at -80 ° C, and then brought back to room temper-
ature for measurement. Raman spectra obtained from 
these samples were analyzed using PCA and LDA based 
on a leave-one-out validation method. The results of an 
eight-group diagnostic algorithm are shown in  Table 5 . 
Seven- and three-group algorithms were also developed; 
all yielding sensitivities and specificities greater than 
82% and 95% respectively, a further breakdown of these 
results can be seen in Table 5. The authors mention that 
 Table 4   Sensitivities and specificities for distinguishing between 
different bladder pathology groups, derived by Stone et al.  [43] . 
Pathology   Sensitivity (%)   Specificity (%) 
Normal   93  99
CIS   83  97
Low-grade cancer   96  96
Medium-grade cancer  78  98
High-grade cancer   98   96 
 CIS,  carcinoma in situ . 
 Table 5   Sensitivities and specificities achieved from algorithms 
generated by Crow et al.  [44] for diagnosing the histological grade 
of bladder tissue. 
Histological grade   Sensitivity (%)   Specificity (%) 
Eight-group algorithm:
   Normal   95   98
   Cystitis   87   98
   CIS   84   99
   G1   71   95
   G2   78   94
   G3   92   98
   G3 squamous   100   99
   G3 Adenocarcinoma  92   100
Seven-group algorithm:
   Normal   96   98
   Cystitis   86   98
   CIS   82   99
   G1/G2   93   99
   G3   93   99
   G3 squamous   100   99
   G3 Adenocarcinoma  92   100
Three-group algorithm:
   Normal   95   97
   Cystitis   90   95
   TCC & CIS   91   98 
 CIS,  carcinoma in situ ; G1, low grade; G2, medium grade; G3, high 
grade; TCC, transitional cell carcinoma. 
the misclassification of G1/G2 TCC could be due to the 
biochemical continuum of the disease or because the 
samples are between G1 and G2 TCC. Further algorithms 
were generated based on staging of pathology (i.e. Ta, 
T1, T2) which also yielded high results, as shown in 
 Table 6 . These algorithms were based on the molecu-
lar composition of the tissue, not the actual degree of 
invasiveness. With this thorough study, Crow et al.  [44] 
extended the use of Raman spectroscopy for the diag-
nosis of bladder pathology and experimentally dem-
onstrated that both the grade and stage of the disease 
 Table 6   Sensitivities and specificities achieved from algorithms 
generated by Crow et al.  [44] for diagnosing the pathological stage 
of bladder tissue. 
Pathological stage   Sensitivity (%)   Specificity (%) 
Three-group algorithm:
   Ta   95  96
   T1   91  94
   T2   80  98
Two-group algorithm:
   Ta   96  96
   T1/T2   96   96 
 Ta, T1, and T2, tumor states according to Table 2. 
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could be identified using Raman classification with high 
sensitivities and specificities. This paper clearly shows 
the capabilities of Raman classification as a valuable 
tool for assisting the pathologist in order to improve the 
accuracy of diagnosis. 
 In 2006, de Jong and colleagues  [45] used Raman 
spectroscopic mapping (mapping refers to biochemical 
images obtained using Raman microspectroscopy and is 
discussed in more detail in Section 5) to create a spectral 
model that could differentiate between tumor and non-
tumor bladder tissue  in vitro . Fifteen snap-frozen bladder 
tissue samples were obtained consisting of normal (2), 
cystitis (3), T2-T3 (9) and TIS (1) which were later con-
firmed by a pathologist using hematoxylin and eosin 
(H&E) staining. Spectra were obtained from each tissue 
sample in a 2-D grid like fashion, with a collection time 
of 20 s, to create a 2-D Raman map of the area. All spectra 
were baseline-corrected, PCA was applied and the spectra 
were grouped into 90 separate clusters, where the spectra 
within each cluster showed a similar biochemical com-
position. Each cluster was assigned a color code, and in 
this way, images were created highlighting areas of similar 
biochemical composition. A CAS was then calculated 
for each cluster and classified as tumor or non-tumor in 
accordance with histopathology. The non-tumor group 
consisted of 37 CAS (representing collagen, muscle fibers 
and inflammation sites), and the tumor group consisted 
of 53 CAS (representing CIS, Ta, T1, T2 and T3). All 90 CAS 
were subjected to further statistical analysis (HCA) with 
Wards cluster algorithm and Euclidean distance measure-
ments, and it was found that one cluster consisted solely 
of non-tumor CAS, whereas the other contained all 53 
tumor CAS and 13 non-tumor CAS, all of which were from 
muscle and inflammation sites misclassified by the algo-
rithm. The author comments that this misclassification 
might be due to the fact that these non-tumor CAS that 
were clustered with tumor tissues contained considerably 
less collagen which is often used to represent the presence 
of cancer. Therefore, to improve the accuracy of diagno-
sis, an LDA model was trained from these 90 CAS that was 
able to distinguish between tumor and non-tumor tissue 
with 100% sensitivity and 95% specificity. A second algo-
rithm based on a leave-one-out cross validation model 
was also developed which resulted in a sensitivity of 94% 
and specificity of 92%. This paper demonstrated the capa-
bility of Raman spectroscopic mapping with a diagnostic 
algorithm to discriminate between tumor and non-tumor 
bladder tissue with a high accuracy and emphasizes the 
potential of the technique to obtain color-coded images 
that could aid in precision surgery, should it be translated 
to an  in vivo setting. 
 And finally, in 2009, Grimbergen et  al.  [11] investi-
gated the potential of a combined diagnostic modality 
using fluorescence with conventional Raman spectros-
copy to improve the diagnosis of bladder cancer. This 
was achieved by applying Raman spectroscopy to bladder 
biopsy samples with and without the presence of 5-ALA  in 
vitro . 5-ALA is a photosensitive dye that leads to an accu-
mulation of protoporphyrin IX (PpIX) in malignant cells 
and is often used in fluorescence cystoscopy to improve 
the detection of bladder cancers. Ninety-two biopsies 
were obtained from 73 patients without 5-ALA during 
TURBT and 38 biopsies with 5-ALA were obtained from 19 
patients that underwent fluorescence-guided endoscopy, 
which were evaluated as normal, cystitis, CIS, G1 TCC, G2 
TCC and G3 TCC by a histopathologist. Standard Raman 
spectra were measured from both biopsy groups, and pre-
processed by applying baseline correction and normaliza-
tion. Raman spectra from fluorescent and non-fluorescent 
groups showed agreement in some bands of significant 
difference with respect to normal and cystitis samples. 
An algorithm was derived to distinguish between cancer 
and non-cancerous tissue, using PCA and LDA, which 
was based on a leave-one-out cross validation of biopsies 
without 5-ALA, and when applied to non-5-ALA samples, 
a sensitivity of 88% and a specificity of 80.1% were 
achieved. However, when applied to the 5-ALA samples, 
a sensitivity of 42% and a specificity of 71.1% were found, 
indicating a change in the biochemistry of bladder tissue 
in the presence of 5-ALA. This resulted in the develop-
ment of a second algorithm based on 5-ALA samples, 
which gave a sensitivity of 75.4% and specificity of 88.7% 
when applied to samples containing 5-ALA. And finally, 
a third algorithm was designed based on a combination 
of Raman spectroscopy and fluorescence prediction meas-
urements that gave a sensitivity of 100% and specificity 
of 80.8% for distinguishing between cancerous and non-
cancerous biopsy samples containing 5-ALA. This com-
bined modality of Raman spectroscopy with fluorescence 
would have an advantage for  in vivo analysis of bladder 
tissue, whereby the author proposes to use 5-ALA-based 
fluorescence for guided resection of bladder cancer where 
5-ALA fluorescence imaging would be used for large area 
screening, and the Raman spectroscopic algorithm would 
be used for accurate diagnosis at a specifically targeted 
region of interest. 
4.3   Raman cystoscopy 
 Raman fiber-optic probes can be easily inserted during 
a cystoscopy procedure to give real-time analysis and 
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classifications of the bladder urothelium. Similar to con-
ventional Raman microspectroscopy, fiber-optic Raman 
probes can also be used to measure samples  in vitro and 
 ex vivo also. This section provides information on the 
progression of fiber-optic Raman probes applied to the 
urinary bladder for diagnostics, which has led to the first 
application of an  in vivo Raman cystoscopy in the past few 
years.  Table 7 shows the Raman capturing methods, laser 
details, substrates used (where applicable) and the wave-
number range recorded in publications that have used 
Raman spectroscopy with a fiber-optic probe to diagnose 
and grade bladder cancer tissue. 
 In 2005, Crow et al.  [46] were the first research group 
to integrate a fiber-optic probe into Raman spectroscopy 
to differentiate between benign and malignant bladder 
tissue  in vitro using a diagnostic algorithm. Bladder tissue 
samples were obtained from 24 patients during TURBT 
and TURP, and classified as normal, cystitis or TCC by a 
uropathologist. Raman spectra were obtained by holding 
the probe in contact with these tissue samples, with an 
acquisition time of 10 s. Spectra were baseline-corrected 
and analyzed with PCA and LDA to result in a sensitivity of 
89% and specificity of 79% for benign tissues, and a sensi-
tivity of 79% and specificity of 89% for malignant tissues, 
thus showing the suitability of using a fiber-optic probe 
for the diagnosis of bladder cancer. The probe used in this 
study was designed to be compatible with the working 
channel of a standard rigid or flexible cystoscope so that 
it could be easily integrated into  in vivo studies, such as 
during endoscopic, laparoscopic or open procedures. 
While it is proposed that the probe could be used  in vivo , 
the reported experimental work focused on bladder tissue 
 in vitro as a proof of concept. 
 In 2009, Grimbergen and colleagues  [47] also inves-
tigated the potential of using Raman spectroscopy for 
bladder tissue diagnosis during cystoscopy by examining 
bladder tissue biopsies  ex vivo using an endoscopic probe. 
In total, 107 bladder tissue samples were obtained from 54 
patients during TURBT, where 5-ALA was used to enhance 
tissue contrast. Samples were graded as normal, cystitis, 
CIS, G1 TCC, G2 TCC, G3 TCC and atypia by a patholo-
gist. Raman spectral measurements were obtained from 
fresh tissue samples (immediately after surgery) with an 
integration time of 2 s. Spectra were pre-processed and a 
model was developed to distinguish between normal and 
malignant tissue using PCA and LDA techniques with a 
leave-one-out cross validation method resulting in a sen-
sitivity and specificity of 78.5% and 78.9% respectively. A 
seven-group algorithm to distinguish between each type 
of pathology was also investigated, but this appeared to 
show a greater number of misclassifications. Whilst this 
study was based on  ex vivo experimentation, these results 
show the possibility of using a Raman spectroscopic probe 
for discerning normal from malignant bladder tissue  in 
vivo in the presence of 5-ALA. 
 Following from the two previous studies  [46, 47] 
involving the application of Raman fiber-optic probes to 
 in vitro and  ex vivo bladder tissue, in 2010, Draga et  al. 
 [8] were the first research group to investigate the use 
of a Raman-based fiber-optic probe for the diagnosis 
of bladder cancer  in vivo . Raman spectra were obtained 
during TURBT procedures on 17 patients without any pho-
tosensitive dyes, 12 patients with 5-ALA and 9 patients 
with HAL, representing a mixture of normal, Ta, T1 and 
T2 bladder tissues  – the pathologic staging was later con-
firmed by two pathologists from biopsy samples taken 
from each patient during the procedure. Spectra were 
measured with a high-volume Raman probe with a pen-
etration depth of 2 mm for integration times of 1 – 5 s. All 
spectra were baseline-corrected and normalized, and three 
diagnostic algorithms were designed using PCA, LDA and 
a leave-one-out cross validation method. The first algo-
rithm was able to distinguish between normal and can-
cerous tissue; the second between normal, non-invasive 
TCC (Ta) and invasive TCC (T1/T2); and the third between 
normal, inflammation and cancer. The first algorithm 
resulted in a sensitivity of 85% and a specificity of 79%, 
and the results of the other two algorithms can be found 
in  Table 8 . It is of note that the authors have suggested 
that the lower sensitivities and specificities might be due 
 Table 7   Capture method, substrates and wavelengths used for Raman spectroscopy-based diagnostic model for diseases associated with 
bladder tissue. 
References   Year   Raman optical 
method 
  Laser 
wavelength (nm) 
  Laser power [at 
sample] (mW) 
  Substrate (if 
applicable) 
  Wavenumber 
range (cm -1 ) 
 [46]   2005  Fiber-optic ( in vitro )  785   [70]    –   800 – 1800
 [47]   2009  Fiber-optic ( ex vivo )   785   NS   Aluminum foil   400 – 1800
 [8]   2010  Fiber-optic ( in vivo )   785   [56 – 89]    –   400 – 1800
 [9]   2012   Fiber-optic ( ex vivo )   785   [30]    –   400 – 1700 
 NS, not specified. 
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to an insufficient sample size. The presence of a photosen-
sitive dye (5-ALA or HAL) was discriminated from tissue 
without any dye with a sensitivity and specificity of 85% 
and 69%, respectively. Diagnosis of normal and cancerous 
bladder tissue in the absence of 5-ALA and HAL resulted 
in a sensitivity of 88% and specificity of 79%, compared to 
a sensitivity of 78% and specificity of 70% in the presence 
of 5-ALA or HAL. Increasing the acquisition time was also 
evaluated, but it was found that longer acquisition times 
did not considerably change the overall predication accu-
racy ( t  ≤  3 s: sensitivity: 85%, specificity: 79%;  t  ≥  3 s: sen-
sitivity: 86%, specificity: 78%). Here, Draga et al.  [8] have 
successfully demonstrated the use of Raman spectroscopy 
for the diagnosis of bladder cancer  in vivo , both with and 
without the presence of a photosensitive dye (5-ALA and 
HAL). This shows the potential of integrating this Raman 
probe into fluorescence cystoscopy procedures to improve 
diagnosis, and further improvements into the design of 
the fiber-optic probe might increase the overall diagnostic 
accuracy in order to achieve results comparable to those 
found in previous  in vitro studies. 
 And most recently, in 2012, Barman et al.  [9] proposed 
the use of a confocal fiber-optic Raman probe to increase 
the specificity (in terms of tissue depth discrimination) for 
bladder cancer diagnosis in this proof-of-concept study 
performed  ex vivo . Bladder tissue samples were excised 
from 14 patients during TURBT, and confirmed as being 
normal or cancerous by a senior uropathologist. Raman 
spectra were obtained from each sample ( ex vivo ) straight 
after surgery using both a high-volume probe and a con-
focal probe to compare the sensitivities and specificities 
achieved for each. The confocal probe was designed by 
placing a pinhole aperture into the high-volume probe to 
decrease the depth of field from 520  μ m to 280  μ m, thus 
suppressing the spectral information from surrounding 
regions and from deeper tissue layers beyond the region 
of interest. All spectra were pre-processed and diagnos-
tic algorithms were developed using PCA and logistic 
 Table 8   Results achieved in algorithms designed by Draga et al.  [8] 
for  in vivo diagnosis of different bladder pathologies. 
Pathology   Sensitivity (%)   Specificity (%) 
(i) Three-group algorithm:
   Normal   79  85
   Non-invasive TCC  41  83
   Invasive TCC   58  76
(ii) Three-group algorithm:
   Normal   78  89
   Inflammation   60  71
   Cancer   71   87 
 TCC, transitional cell carcinoma. 
regression analysis along with a leave-one-out cross vali-
dation. The high-volume probe produced a sensitivity 
of 85.7% and specificity of 85.7%, whereas the confocal 
probe has a sensitivity of 85.7% and specificity of 100%. It 
should be noted that this diagnostic algorithm was based 
on only two PCs, thus emphasizing the robustness of the 
confocal Raman probe. The significant increase in speci-
ficity values of the confocal probe in comparison to the 
high-volume probe are associated with the smaller depth 
of field values, giving this particular device an advantage 
in the application of Raman probes for real-time  in vivo 
diagnosis of bladder pathology. This confocal probe has 
also shown potential to be used to discriminate between 
different grades and stages of tumors that might improve 
the overall pathological diagnosis. 
 In summary, in this section it has been shown that 
Raman spectroscopy can be used to accurately discrimi-
nate between healthy and cancerous bladder tissue, as 
well as being able to classify the exact grade (or stage) of 
the tissue sample, both  in vivo and  in vitro . This develop-
ment paves the way for the potential integration of Raman 
spectroscopy into a clinical setting to improve upon 
the accuracy of diagnosing bladder cancer, and there-
fore, have the ability to improve upon patient outcome. 
Another advantage of this technique is that it is minimally 
invasive, and can applied  in vivo during a cystoscopic pro-
cedure or  in vitro from biopsy samples as discussed in the 
previous section.  Table 9 provides a summary of all results 
to date generated using Raman spectroscopic techniques 
for bladder tissue diagnosis applied  in vivo and  in vitro / ex 
vivo . These results clearly show the potential of this robust 
technique becoming a standard clinical procedure for 
highly accurate bladder disease diagnosis. 
4.4   Raman cytology 
 Within the last 5 years, studies have begun investigating 
the potential use of Raman spectroscopy for analyzing 
and classifying disease from bladder cells rather than 
tissue, thus moving to a completely non-invasive proce-
dure of detecting bladder disease from voided urine. This 
technique has the potential of replacing standard biopsy 
or cytology procedures. In this section the current progress 
in this area is reviewed and the results achieved using dif-
ferent Raman optical methods are highlighted. 
 To prepare bladder cells for Raman spectral meas-
urements, cells were either cultured from cell lines (for 
proof of concept studies) or obtained from voided urine. 
Cell lines are cultured within a nutrient medium (typically 
containing fetal calf serum). These cells are then removed, 
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 Table 9   List of tissue details, statistical methods used and results achieved from each referenced study in the development of a diagnostic 
model for bladder cancer in tissue, either using Raman microspectroscopy or a Raman fiber-optic probe. 
References   Source   Storage   Number of 
patients 
(samples) 
  Tissue status   Statistics   Sensitivity (%)   Specificity (%) 
 [8]   TURBT    In vivo     Mixture of normal, 
Ta, T1 and T2
  PCA, LDA   85  79
    With 5-ALA   12      
    With HAL   9       
    Without PDD   17       
 [9]   TURBT   Fresh samples   14 (14)  Normal   PCA, LRA   85.7  100.0
      (14)  Cancerous      
 [11]   Biopsy   Without 5-ALA   73 (26)  Normal   PCA, LDA   88.0  80.1
    Snap-frozen to -80 ° C   (14)  Cystitis      
      (2)  CIS      
      (14)  G1      
      (25)  G2      
      (11)  G3      
 [11]   Biopsy   With 5-ALA   19 (20)  Normal   PCA, LDA   75.4  88.7
    Snap-frozen to -80 ° C   (6)  Benign     100.0 (FL + Raman)  80.8 (FL + Raman)
      (1)  CIS      
      (3)  G1      
      (6)  G2      
      (2)  G3      
 [43]   Cystoscopy   Snap-frozen to -80 ° C   12 (12)  Normal   PCA, LDA   93.0  99.0
        CIS     83.0  99.0
        LGC     96.0  96.0
        MGC     78.0  98.0
        HGC     98.0  96.0
 [44]   TURBT, TURP and 
cystoscopy
  Snap-frozen to -80 ° C   22 (22)  Normal   PCA, LDA   95.0  98.0
    10 (10)  Cystitis     87.0  98.0
      2 (2)  CIS     84.0  99.0
      9 (9)  G1     71.0  95.0
      20 (21)  G2     78.0  94.0
      7 (9)  G3     92.0  98.0
      1 (1)  G3 squamous     100.0  99.0
      1 (1)  G3 adenocarcinoma    92.0  100.0
 [45]   NS   Snap-frozen 
(temperature NS)
  2 (2)  Normal   PCA, LDA, 
CAS, HCA
  94.0  92.0
    9 (9)  T2 – T3    
      1 (1)  TIS      
      3 (3)  Cystitis      
 [46]   Cystoscopy, 
TURBT and TURP
  Snap-frozen to -80 ° C   24 (11)  Normal   PCA, LDA   89.0 (benign)  79.0 (benign)
    (8)  Cystitis     79.0 (malignant)  89.0 (malignant)
      (2)  G1      
      (7)  G2      
      (1)  G3      
 [47]   TURBT   Fresh samples   54 (42)  Normal   PCA, LDA   78.5  78.9
      (16)  Cystitis      
      (14)  CIS      
      (3)  G1      
      (15)  G2      
      (10)  G3      
         (7)   Atypia          
 TURBT, transurethral resection of bladder tumor; TURP, transurethral resection of the prostate; FL, fluorescence cystoscopy; 5-ALA, 5-ami-
nolevulinic acid; HAL, hexaminolevulinate; PDD, photodynamic diagnosis; PCA, principal components analysis; LDA, linear discriminant 
analysis; LRA, logistic regression analysis; CAS, cluster averaged spectra; HCA, hierarchical cluster analysis. 
 Ta, T1, T2, and T3, tumor states according to Table 2; TIS/CIS,  carcinoma in situ ; G1, low grade; G2, medium grade; G3, high grade; LGC, 
 low-grade carcinoma; MGC, medium-grade carcinoma; HGC, high-grade carcinoma. 
 NS, not specified. 
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and can be analyzed live or after a chemical fixation has 
been applied. It is also possible to suspend cells in a urine 
solution in order to observe the effects of urine on these 
cells. Otherwise, bladder cells can be acquired from fresh 
voided urine via a centrifugation process. 
 To analyze bladder cells using Raman spectroscopy, 
the cells can be deposited onto a substrate using a cyto-
spin or they can be analyzed using an optical Raman twee-
zers technique which isolates a cell within an optical trap, 
and allows for Raman spectral data only to be obtained 
from the individual cell, thus reducing background con-
tributions.  Table 10 displays the Raman optical methods 
applied, the details of the laser used, substrates used (if 
any) and the wavenumber range over which data were 
collected and analyzed in studies investigating the use of 
Raman spectroscopic methods to diagnose bladder cancer 
from urothelial cells. 
 The first study to analyze bladder cells using Raman 
spectroscopy was investigated by Harvey et  al.  [36] in 
2008, where Raman optical tweezers were used to trap 
and analyze both live and chemically fixed bladder cells, 
and to differentiate between normal and cancerous cells. 
In the first part of this study, the Raman tweezers tech-
nique was applied to discriminate between a malignant 
bladder cell line (MGH-U1  – otherwise known as T24 
 [48] ) and a malignant prostate cell line (PC-3). All of the 
cells were fresh and stored in phosphate buffered saline 
(PBS) before and during measurement. Raman spectra 
were obtained using a 514.5  nm laser, and all spectra 
were pre-processed by removing the background contri-
bution, followed by extended multiplicative signal cor-
rection. PCA was applied to the spectra and the resulting 
PCA plot of this shows that the two cell types can be 
identified as separate cell groups. The second part of 
the study investigated the use of Raman tweezers to dis-
criminate between the following alcohol-fixed cell lines: 
malignant bladder cells (MGH-U1), malignant prostate 
cells (LNCaP, PC-3) and benign prostate cells (BPH). All 
cells fixed using SurePath TM (BD Diagnostics, NJ, USA) 
 Table 10   Capture method, substrates and wavelengths used for Raman spectroscopy in analyzing bladder cells. 
References   Year   Raman optical 
method 
  Laser 
wavelength (nm) 
  Laser power [at 
sample] (mW) 
  Substrate (if 
applicable) 
  Wavenumber 
range (cm -1 ) 
 [36]   2008  Tweezers   514.5  NS   –   NS
 [32]   2009  Tweezers   514.5  400 [100], 200 [32.6]   –   NS
 [12]   2011  Conventional   532  NS  Aluminum   350 – 3560 a 
 [13]   2011   Modulated   785   100 [8]   Quartz   500 – 2100 
 a Exact wavenumber range not given, assumption made from Raman spectra provided. 
 NS, not specified. 
and stored at  < 4 ° C. Raman spectra were recorded and 
pre-processed the same way as for live cells. Spectra were 
then subjected to PCA and LDA to differentiate between 
each cell group based on a training and test validation 
method, the results of which are shown in  Table 11 . This 
initial study based on the application of Raman tweezers 
to differentiate between different urological cell lines 
has shown the diagnostic potential of this technique for 
detecting both bladder and prostate cancer. 
 In 2009, Harvey et  al.  [32] continued on from this 
initial study to further investigate the application of 
Raman tweezers to classify cultured cell lines that have 
been chemically fixed using either SurePath TM or forma-
lin, as well as investigating the effect of exposure to urine 
on these cells. Raman tweezers were first used to distin-
guish between the following cell lines fixed with Sure-
Path TM : malignant bladder cells (MGH-U1), malignant 
prostate cells (LNCaP, PC-3), normal prostate cells (PNT2-
C2) and benign prostate cells (BPH). The Raman tweezers 
configuration consisted of two lasers, whereby cells were 
trapped and analyzed using a 514.5 nm laser (laser power 
of 200 mW used; 32.6 mW at sample surface), and a sec-
ondary 1064 nm laser was used to retain the cell in the 
optical trap. Raman spectra were obtained in this method 
from 100 MGH-U1, 104 BPH, 104 LNCaP, 115 PC-3 and 110 
PNT2-C2 cells. All spectra were pre-processed by removing 
the background contribution, adding a correction factor to 
adjust the 880 cm -1 Raman peak to the baseline (the author 
suggests that this peak is most likely contamination from 
 Table 11   Results achieved by Harvey et al.  [36] using Raman twee-
zers to discriminate between fixed cell lines using PCA and LDA. 
Cell line   Sensitivity (%)   Specificity (%) 
Bladder cancer (MGH-U1)   91.7  96.4
Benign prostate (BPH)   93.8  97.1
Prostate cancer (PC-3)   72.7  98.2
Prostate cancer (LNCaP)   90.2   94.5 
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the SurePath TM solution). Extended multiplicative scatter-
ing correction, vector normalization and mean centering 
were also applied. A diagnostic model was designed by 
applying PCA and LDA to the spectra, and the results can 
be seen in  Table 12 , showing that is it possible to clearly 
distinguish between each group of cells after being fixed 
with SurePath TM . However, the authors have noted that 
the MGH-U1 and PC-3 cells were found to be larger in Sure-
Path TM than when unfixed. 
 The second section of this study was based on the 
use of Raman tweezers to distinguish between the fol-
lowing formalin-fixed cells: malignant bladder cells 
(MGH-U1), urethral cells (from patients), benign prostate 
cells (BPH), normal prostate cells (PNT2-C2) and malig-
nant prostate cells (LNCaP, PC-3). For these experimental 
measurements, the laser power was increased to 400 mW 
(100 mW at the sample surface), and as a result, a sec-
ondary, counter-propagating beam was not required for 
these cells. Raman spectra were recorded from 135 cells 
in each group, and spectra were pre-processed using a 1:1 
background subtraction, extended multiplicative scatter-
ing correction, vector normalization and mean centering. 
For classification, PCA and LDA were applied, with blind 
and double blind testing, to yield the results shown in 
Table 12. 
 Further classification models (based on classifying 
four cells at a time) were also developed, the results of 
which can be found elsewhere  [32] also show good separa-
tion between each cell type. A comparison between both 
chemical fixing methods shows that formalin has a better 
diagnostic performance and a greater S/N, although this is 
 Table 12   Results achieved by Harvey et al.  [32] using Raman 
tweezers to discriminate between different cell lines that have been 
fixed with SurePath TM or formalin. 
Cell line   Sensitivity (%)   Specificity (%) 
SurePath TM fixed:
   MGH-U1   93.8  92.1
   BPH   79.2  99.1
   PNT2-C2   72.7  94.5
   PC-3   95.1  95.7
   LNCaP   78.8  97.8
Formalin fixed:
   MGH-U1   88.2  98.1
   Urethral cells  97.8  98.1
   BPH   100.0  99.2
   PNT2-C2   99.5  98.4
   PC-3   98.0  99.6
   LNCaP   93.5   99.6 
 MGH-U1, malignant bladder cells; BPH, benign prostate cells; PNT2-
C2, normal prostate cells; PC-3 and LNCaP, malignant prostate cells. 
due to the higher laser power used. There was also no con-
tamination in spectra from the formalin solution, whereas 
a significant contribution was found in the SurePath TM 
spectra. 
 Finally, the last part of this study was to determine 
the effects of exposure to urine on the ability to classify 
cells. To investigate this, all cells (MGH-U1, BPH, LNCaP 
and PC-3) were unfixed and stored at room temperature 
before being exposed to urine for the following time dura-
tions: 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h 
and 12 h. Raman spectra were obtained using the same 
set-up as used for the formalin-fixed cells, and spectra 
were also pre-processed using the same method. PCA 
and LDA were applied to the spectra, and it was shown 
that in general the prediction values do not deteriorate 
over 12 h. On the contrary, a drop in prediction values 
was noted between 30  min and 45 – 60 min, the author 
contributed this to a reduction in the stress-response 
proteins; otherwise results were similar to before urine 
exposure. Overall, this study has shown the potential of 
using Raman tweezers to distinguish between bladder 
cells and prostate cells, and also between cancerous and 
non-cancerous cells. It has also been shown that it is pos-
sible to accurately classify cells that have been fixed with 
SurePath TM and formalin, and that up to 12 h exposure to 
urine does not affect the ability to distinguish between 
the different cell groups. 
 In 2011, Shapiro et al.  [12] investigated the possibil-
ity of applying Raman spectroscopy to bladder epithelial 
cells from voided urine in order to determine whether or 
not TCC was present. For this study, fresh urine samples 
were obtained from 340 patients (116 without TCC, 92 
with low-grade TCC and 132 with high-grade TCC). To 
prepare the urine samples for Raman spectroscopic 
measurements, they were spun at 3000  rpm for 5 min, 
the supernatant was removed, and the pellet was resus-
pended in distilled water. It was then centrifugated at 
3000  rpm for 5  min again and the remaining superna-
tant removed. Filtration was carried out to capture the 
bladder epithelial cells and to wash off other constitu-
ents. The epithelial cells were washed to resuspend them 
before being placed into a cytospin chamber and spun 
at 1100 rpm for 5 min and deposited onto an aluminum 
slide. Raman spectra were obtained from an average 
of five cells per slide using a 532 nm laser; all spectra 
were baseline-corrected and normalized. The resulting 
spectra showed a positive 1584 cm -1 Raman peak for can-
cerous cells that was not present for non-malignant cells. 
The authors developed a model based only on this peak 
(no PCA or LDA required) that could classify spectra as 
normal, low-grade TCC or high-grade TCC by evaluating 
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the height of the 1584 cm -1 peak above the baseline at 
1500 cm -1 and using a set of specific thresholds to classify 
each spectrum with an overall sensitivity of 92% and a 
specificity of 91%. A second part of this study involved 
comparing the Raman spectra from these bladder cells 
with spectra obtained from bladder tissue samples. 
These bladder tissue samples were obtained from surgi-
cal touch preps and were frozen prior to Raman measure-
ments. This study showed that the spectra from bladder 
cells and tissue were virtually identical, and that it is 
possible to determine the histological grade of both cells 
and tissue based on the height of the distinct Raman 
peak at 1584 cm -1 . 
 In 2011, Canetta et  al.  [13] developed the first appli-
cation of modulated Raman spectroscopy (MRS) for the 
identification of human bladder cell lines in urine, whilst 
monitoring cell viability after exposure to urine, and 
the differences between standard Raman spectroscopy 
(SRS) and MRS for cell classification were also examined. 
Healthy human urothelial cells (SV-HUC-1) and malignant 
bladder cells (MGH-U1) were cultured, and then exposed 
to a solution containing two parts fresh urine and one 
part PreservCyt (Cytec, UK) for the following time dura-
tions: 0 h (control), 30 min, 3 h and 6 h. This was then 
centrifugated for 10 min and the cells were resuspended 
in PreservCyt for storage. Prior to Raman spectral meas-
urements, the cells were washed with PBS before being 
resuspended in 100  μ l of PBS and placed in a sample 
chamber between a quartz slide and a quartz coverslip. 
Cells were allowed  ∼ 30 min to sediment onto the quartz 
before Raman measurements were obtained. Spectra 
were recorded from 40 urothelial cells and 40 bladder 
cancer cells for each of the urine exposure times using 
a 785 nm modulated laser (modulated with a ramp wave 
of 50% symmetry, 40 mHz modulation frequency, 60 GHz 
modulation amplitude  – corresponding to 0.2 nm). For 
each cell, 40 stacked spectra were recorded with a total 
integration time of 200 s. PCA was applied to the spectra 
and a non-specified algorithm was used for classifica-
tion, the results of which can be seen in  Table 13 . These 
results show that exposure to urine affects the cell ’ s bio-
chemistry causing a reduction in the S/N in the spectra. 
However, it is still possible to distinguish between both 
cell groups using MRS, even after exposure to urine for 
6 h. 
 The second part of this study involved monitoring 
cell viability in urine using 1% Fast Green dye (Sigma 
Chemical Company, MO, USA), and it was found that 
after 1 h, the viability of the cancer cells decreased to 
 ∼ 60% and  ∼ 64% for healthy cells, and the reproductive 
capacity of both cells decreased rapidly after exposure 
 Table 13   Results obtained from Canetta et al.  [13] for classifying 
fixed urothelial cells (SV-HUC-1) and fixed bladder cancer cells 
(MGH-U1), for assigned exposure to urine times, using both stand-
ard Raman spectroscopy and modulated Raman spectroscopy. 
Method   Urine exposure 
times (h) 
  Sensitivity 
(%) 
  Specificity 
(%) 
Modulated Raman 
spectroscopy (PCA)
  0   98   95
Modulated Raman 
spectroscopy (PCA)
  6   80   87
Standard Raman 
spectroscopy (PCA 
and Fourier Transform) 
  0   97   72 
 PCA, principal components analysis. 
to urine. This mirrors the Raman data obtained from dif-
ferent exposure times where changes in the biochem-
istry can be seen with progressing exposure times. The 
robustness of MRS in comparison to SRS was then inves-
tigated by comparing the Raman spectra obtained from 
each method for fixed urothelial cells and fixed bladder 
cancer cells not exposed to urine (control group). The 
SRS spectra showed a strong autofluorescence signal 
from the quartz substrate, and Raman peaks from the 
cells are not well defined. On the other hand, the MRS 
spectra allow for Raman peaks to be clearly observed. 
PCA was applied to both the SRS and MRS spectra to 
discriminate between both cell groups, and the Fourier 
Transform was also applied to the SRS spectra in order 
to distinguish between the slow varying background 
and the Raman peaks, the results of which can also be 
seen in Table 13. In the Fourier domain, the background 
signals were present at low frequencies, whereas the 
Raman signals were present at high frequencies; there-
fore the Fourier Transform was able to separate the most 
important Raman signals from the background. Higher 
sensitivities and specificities were achieved with MRS, 
which may be due to the better S/N obtained by filter-
ing out the Raman peaks associated with the biological 
cells from the fluorescence background signals. It has 
also been noted that the healthy urothelial cells show 
relatively strong protein and carbohydrate Raman peaks 
(1100 – 1300 cm -1 region) in comparison to the cancerous 
cells, and there was an increase in ring breathing modes 
for the cancerous cell spectra (669, 727, 785, 828, 1095, 
1578 cm -1 ) indicating a higher concentration of deoxyri-
bonucleic acid (DNA) in malignant cells. 
 In 2013, Praveen et al.  [49] further developed modu-
lated Raman spectroscopy for the analysis of bladder 
cancer cells, with the aim of reducing acquisition 
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times in order to achieve high throughput cell screen-
ing. Healthy human urothelial cells (SV-HUC-1) and 
malignant bladder cells (MGH-U1) were cultured, and 
placed into a sample chamber built from a quartz slide 
and a quartz cover slip. In this study, various experi-
mental parameters were varied to minimize acquisi-
tion time whilst maintaining complete discrimination 
between both cell groups (using PCA). The parameters 
under investigation were the range within which the 
wavelength was modulated, number of cycles, sam-
pling rate and acquisition time. Results from this study 
have shown that the optimum modulation amplitude 
was  Δ λ = 0.32 nm ( Δ v = 160 GHz) or greater, and that the 
sample rate did not affect the S/N of the Raman peaks 
provided there were three or more wavelengths being 
sampled. Using these parameters, the authors were able 
to discriminate between healthy and cancerous bladder 
cells with a total acquisition time of 6 s (i.e. 2 s per acqui-
sition cycle at a sampling rate of 3), with a laser power 
of 200 mW maintained at the sample. This study has 
shown the potential of using modulated Raman spec-
troscopy for the classification of bladder cells with a 
significantly shorter acquisition time, thus highlighting 
the potential use of this technique for higher throughput 
Raman measurements based on flow cytometry. 
 In summary, it has been shown that Raman optical 
tweezers can be used to discriminate between normal 
and cancer bladder cell lines, and also between bladder 
and prostate cell lines. This method has been applied 
to live cells, cells chemically fixed (with formalin or 
SurePath TM ), and cells that have been exposed to urine 
for up to 12 h, all resulting in high classification predic-
tion values. Conventional Raman microspectroscopy 
has also been applied to discriminate between normal 
and cancerous cells obtained from voided urine based 
on thresholding the Raman peak at 1584 cm -1 , which is 
seen in both the spectra from bladder cells and bladder 
tissue samples. In study by Canetta et al.  [13] (the only 
one to date using cells from voided urine) Raman micro-
spectroscopy was shown to have diagnostic sensitivity 
of 92% and specificity of 91%. And finally, it is possible 
to differentiate between normal and cancerous cell lines 
using SRS and MRS, when cells have been fixed or incu-
bated in urine for up to 6 h, the latter showing improved 
results for using relatively inexpensive quartz substrates. 
It has been noted that while urine affects the cells bio-
chemistry, the results obtained are similar to those of 
control cells  [12, 32] . Thus, this shows how robust Raman 
spectroscopic techniques are for discriminating between 
bladder cells regardless of how they are prepared or 
stored. 
5   Investigating the etiology of 
bladder cancer using Raman 
spectroscopy 
 In the last two decades, there has been considerable 
interest in the use of Raman spectroscopy in identifying 
the biochemistry of bladder tissue, and the potential of 
using this to detect differences between the biochemis-
try of normal tissue with cancerous tissue, which would 
not only assist in early detection of disease, but also aid 
in understanding the etiology of bladder cancer. The 
main methods used for this are the creation of a reference 
database of component spectra, least squares fitting and 
Raman spectroscopic mapping. These techniques can be 
used to highlight regions of different tissue composition, 
and could be integrated into surgical procedures to iden-
tify border regions between normal and diseased tissue 
sections, thus improving patient outcome. Another appli-
cation is to identify the biomolecular changes occurring 
with disease progression. A brief introduction into each 
of these methods is given below while  Table 14 shows the 
Raman capturing methods, laser details, the substrates 
used and the wavenumber range recorded in publica-
tions that have used Raman spectroscopy to analyze the 
biochemistry of bladder tissue. Further details from each 
publication can be found below and a summary of the 
main Raman shift peaks associated with each pathology is 
given in  Table 15 . In the discussion that follows, all tissue 
samples are human unless otherwise specified.
 –  Reference database: To create a reference database, 
spectra are recorded from a selection of Raman active 
biological compounds (e.g. collagen, DNA, actin, 
cholesterol). These spectra are stored in a database, 
and are compared to the spectra obtained from the 
tissue sample using multivariate techniques or least 
squares (see below). This method can be used to 
determine which components are present and absent 
and in what concentrations, and therefore can be 
used to identify the biomolecular composition and 
pathological status of the sample. 
 –  Least squares: Least squares techniques, such as 
ordinary least squares (OLS) and non-negative least 
squares (NNLS) have been used for Raman spectral 
data in urinary bladder diagnostics. These methods 
are based on a mathematical technique of finding 
the best fit for a given set of data by minimizing the 
sum of the squares of the offset points in the dataset. 
This approach can be used to fit the mean spectra of 
the reference components to the mean spectra of the 
tissue sample of interest. The resulting biochemical 
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 Table 14   Capture method, substrates and wavelengths used for Raman spectroscopy in analyzing the biochemistry of bladder tissue. 
References   Year   Raman optical method   Laser 
wavelength (nm) 
  Laser power [at 
sample] (mW) 
  Substrate (if 
applicable) 
  Wavenumber 
range (cm -1 ) 
 [50]   1995  Conventional   830   [90 – 480]   Aluminum   800 – 1800 a 
 [51]   2002  Mapping   847   NS   Calcium fluoride   400 – 1800
 [51]   2002  Fiber-optic ( in vivo )   830   [170]    –   800 – 1800
 [52]   2003  Mapping   845   NS   Calcium fluoride   400 – 1800
 [53]   2005  Kerr-gated   488   [5]   Quartz & uric 
acid
  500 – 1900 a 
 [45]   2006  Mapping   845   100   Calcium fluoride   400 – 1800
 [54]   2007  Conventional   830   300 [100]   Calcium fluoride   300 – 1900 a 
 [11]   2009  Conventional   830   300 [100]   Calcium fluoride   NS
 [8]   2010  Fiber-optic ( in vivo )   785   [56 – 89]    –   400 – 1800
 [12]   2011   Conventional   532   NS   Aluminum   350 – 3560 a  
 a Exact wavenumber range not given, assumption made from Raman spectra provided. 
 NS, not specified. 
spectral model can indicate the main biochemical 
components for that tissue. A disadvantage of least 
squares is the sensitivity of the fit to any collinearity 
in the components. Therefore it is often necessary to 
remove some of the components whose spectra vary 
together in a co-linear manner. 
 –  Raman spectroscopic mapping: Raman spectroscopic 
mapping is another method of obtaining information 
from conventional Raman spectroscopy. This is 
where a 2-D  ‘ map ’ of the intensity of Raman peaks 
are recorded with respect to spatial positioning. This 
is achieved by scanning the biological sample in a 
raster-mode, and recording spectra from a series of 
grid-points using confocal Raman microspectroscopy. 
It is possible to apply further statistical analysis, such 
as PCA and cluster analysis, to arrange these spectra 
into distinct groups representing regions of different 
biochemical composition (such as collagen, muscle, 
etc.), which can then be applied to generate a color-
coded  ‘ map ’ of the tissue area indicating regions of 
similar composition, thus highlighting regions of 
damaged or diseased tissue. 
 In 1995, in what is believed is the first study of the bio-
chemistry of bladder tissue using Raman spectroscopy, 
Feld et al.  [50] investigated the potential of using Raman 
spectroscopy for providing information about the different 
molecular composition of normal and cancerous human 
bladder tissue. Bladder tissue samples were obtained 
during routine surgical procedures, pathology was con-
firmed by a board-certified pathologist, and samples were 
stored at -80 ° C prior to measurements. Tissue samples 
were kept moist at all times while the Raman spectra were 
being obtained. From these spectra, it was found that most 
spectral differences were associated with an increased 
content of nucleic acid in bladder carcinoma tissues. All 
spectra were largely dominated by proteins, but bladder 
cancer spectra were found to contain more nucleic acids 
than normal tissue and the lipid content of normal tissue 
was found to be higher than that of cancerous tissues. This 
initial study demonstrated the potential of using Raman 
spectroscopy for determining the differences in biochemi-
cal composition between both tissue groups and laid the 
basic ground work for more research in the area. 
 In 2002, de Jong and colleagues  [51] used a combi-
nation of Raman spectroscopic mapping ( in vitro ) and 
fiber-optic Raman spectroscopy ( in vivo and  in vitro ) to 
determine the composition of bladder wall tissue obtained 
from four guinea pigs with healthy bladders. This study 
was carried out in two parts with the overall goal of inves-
tigating the potential of using Raman spectroscopy to 
analyze the structural changes in bladder wall tissue that 
might be associated with bladder function. Firstly, Raman 
spectroscopic maps were created from the three bladder 
wall layers (i.e. urothelium, lamina propria and muscle 
layer)  in vitro by collecting 500 – 700 spectra in a 2-D grid 
with a collection time for each element of 60 s. All spectra 
were pre-processed by wavenumber calibration, baseline 
correction and normalization. A combination of PCA and 
K-means clustering techniques were applied to gener-
ate four clusters, representing the urothelium, lamina 
propria, muscle layer and an absence of tissue (i.e. holes 
in tissue or tissue edges). Raman spectroscopic measure-
ments obtained from collagen I, collagen III and actin 
compounds were used for compositional analysis of the 
tissue maps designed for each bladder wall layer, and it 
was found that the muscle layer consisted mainly of actin 
(and myosin), the lamina propria was composed mainly of 
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collagen, and the urothelium mostly contained fatty acids 
(1081, 1261, 1299, 1439 and 1659 cm -1 ), with no collagen at 
all found in the urothelium. The tissue was then stained 
with hematoxylin and eosin (H&E), and a standard digital 
photograph of the region was taken. Distinct similarities 
between the bladder wall structure in the Raman map and 
the photograph are clearly seen in  Figure 9 . 
 The second part of this study investigated Raman 
spectroscopic measurements of bladder wall tissue  in vivo 
using a fiber-optic probe in both full and empty guinea pig 
bladders. Using the fiber-optic set-up, a reference data-
base of component spectra was initially created using iso-
lated bladder wall layers (urothelium, lamina propria and 
muscle layer) and guinea pig urine  in vitro . This database 
was then used to determine the relative signal contribu-
tion of each tissue layer during  in vivo measurements using 
PCA, K-means clustering and NNLS fitting techniques. For 
full bladder measurements, 51% of the Raman spectrum 
was from urine and following subtraction of this signal, 
the remaining Raman signal was found to consist of 65% 
muscle, 16% lamina propria and 19% urothelium. This 
study of the biochemistry of bladder tissue was the first to 
employ a compositional analysis of bladder tissue using 
Raman spectra. The study demonstrated that bladder 
wall layers are easily distinguishable using Raman spec-
troscopy techniques, both  in vivo and  in vitro , even when 
 Table 15   Distinctive Raman peaks reported as being associated with each pathology in the below listed references for bladder tissue. 
Raman shift (cm -1 )   Peak assignment   References 
Normal tissue
   875   Hydroxyproline    [8] 
   1080   C-N stretching of proteins, lipids    [8] 
   1081   Fatty acids (urothelium)    [51] 
   1220 – 1300   Amide III, collagen    [8] 
   1261   Fatty acids (urothelium)    [51] 
   1289   Fatty acids (urothelium)    [51] 
   1303   CH 3 , CH 2 , lipids, DNA    [8] 
   1439   Fatty acids (urothelium)    [51] 
   1446   CH 2 deformation, lipids, proteins    [8] 
   1657   Amide I, C = C lipid stretch, phospholipids    [8] 
   1659   Fatty acids (urothelium)    [51] 
Cancer tissue
   680   DNA    [8] 
   789   DNA    [8] 
   1003   Phenylalanine    [8] 
   1170   Tyrosine    [8] 
   1180   DNA    [8] 
   1208   Tryptophan, phenylalanine    [8] 
   1370   DNA, lipids    [8] 
   1386   CH 3 , lipids    [8] 
   1540 – 1580   Tryptophan, DNA, phenylalanine    [8] 
   1584    –    [12] 
   1600 – 1620   Phenylalanine, tyrosine, tryptophan    [8] 
Damaged tissue
   857   Lactate    [52] 
   1005   Proteins    [52] 
   1079   Proteins    [52] 
   1321   Proteins    [52] 
   1415   Lactate    [52] 
   1447   Proteins    [52] 
   1455   Lactate    [52] 
   1659   Proteins    [52] 
Inflammation
   526    –    [8] 
   572    –    [8] 
   1485   DNA    [8, 55] 
   1569    –    [8] 
 DNA, deoxyribonucleic acid. 
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urine is present. The results shown in the paper indicated 
the potential for the use of Raman microspectroscopy, 
Raman mapping, and Raman-based compositional analy-
sis for monitoring the changes in biomolecular composi-
tion of bladder wall tissue and the ability to relate these to 
changes in bladder functionality. 
 In 2003, de Jong et  al.  [52] further investigated the 
potential of Raman spectroscopic mapping by applying 
it to unfixed sections of bladder wall tissue, obtained 
from guinea pigs, in order to determine the differences 
between normal and damaged bladder wall composition 
caused by partial urethral obstruction. Raman maps were 
created from four normal bladders and three obstructed 
bladders, whereby each grid element spanned 2 – 3  μ m 2 of 
tissue with a signal collection time of 20 s that was used 
to obtain an area averaged spectrum. All spectra were 
initially baseline-corrected and wavenumber calibrated, 
and a combination of PCA and K-means clustering were 
applied to obtain Raman maps that grouped together, and 
color-coded, the spectral characteristics of different tissue 
regions in a 2-D grid. As in their previous study, the Raman 
maps were compared with digital photographs of the same 
tissue region stained with H&E, and the contours of the 
tissue maps match the image as can be seen in  Figure 10 . 
From the compositional analysis, it was found that the 
healthy tissue map contained only two clusters, one 
mainly showing characteristics of collagen, the second 
showing a mixture of actin and myosin. PCA and K-means 
clustering applied to the damaged tissue showed three 
clusters, two of which were similar to the clusters found 
in the healthy tissue. For the additional cluster, spectral 
characteristics of both collagen and muscle were found, 
indicating the presence of collagen infiltration surround-
ing muscle fibers which was not present in normal tissue. 
Collagen infiltration is often associated with structural 
damage in the bladder, however to determine the extent 
of the collagen infiltration it was necessary to remove the 
collagen that naturally surrounds muscle fibers. Raman 
spectra also showed an increase in lactate (857, 1415, 1455 
cm -1 ) and glycogen (857, 1005, 1079, 1321, 1447, 1659 cm -1 ) 
in the damaged tissue which the authors suggest might 
indicate that ischemia is related to increased glycogen 
levels and collagen infiltration. In this study, de Jong et al. 
 [52] again demonstrated the use of Raman spectroscopic 
mapping for investigating the biochemistry of bladder 
wall tissue, and they indicated how its ability to detect 
changes in molecular composition could be utilized as a 
diagnostic tool. 
 Prieto et  al.  [53] extended on from the work of de 
Jong et al.  [52] in the analysis of bladder wall layers using 
Raman spectroscopy, but instead of using the Raman 
mapping technique, Prieto used a Kerr-gated Raman 
spectroscopy procedure consisting of a pulsed laser, two 
crossed polarizers and a 4 ps optical Kerr shutter. A normal 
human bladder sample, obtained via biopsy during a cys-
toscopic procedure, snap-frozen and stored at -80 ° C prior 
A
B
 Figure 9   Comparison of bladder wall tissue observed with (A) Raman spectroscopic mapping, and (B) H&E staining taken with standard 
photography  – indicating regions of urothelium (U), lamina propria (LP) and muscle (M). Images obtained from de Jong et al.  [51] , repro-
duced with permission from Elsevier. 
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to measurements, was analyzed using this Kerr-gated 
set-up on a quartz cell substrate containing uric acid. This 
technique allows for spectra to be obtained from differ-
ent depths in the tissue as signals emerge from the tissue 
at different times depending on their penetration depth. 
Therefore, changes in shift peak intensities were observed 
as the temporal position of the Kerr gate was varied which 
could then be related to different depth measurements 
with acquisition times, which correspond to the urothe-
lium, lamina propria and muscle layer, and eventually, all 
tissue signals were lost and uric acid peaks appeared (662 
and 803 cm -1 ). Whilst this depth profiling method showed 
potential for the investigation of bladder wall layers and 
ability to assess bladder pathology, it was reported that 
the instrumentation (which filled two rooms) was too 
large to be used in a hospital setting in the near future. 
 In 2006, de Jong et  al.  [45] used a combination of 
Raman spectroscopic mapping and compositional analy-
sis to evaluate the main molecular differences between 
tumor and non-tumor bladder tissue and gain insight 
into the biochemical alterations that are associated with 
pathogenesis. Raman spectroscopic maps were generated 
from 15 bladder tissue specimen, five of which were non-
tumor (normal and cystitis) and the remaining 10 were 
tumor tissues (TIS, T1 and T2), with a signal collection 
time of 20 s. To perform compositional analysis on these 
spectra, a large reference database of component spectra 
was employed, Raman spectra of 18 different compounds 
were used in total; collagen I, collagen III, actin, albumin, 
DNA, ribonucleic acid (RNA), cholesterol,  β -carotene, gan-
gliosides, glycogen, phosphatidylcholine, phosphatidyle-
thanolamine, arachidonic acid, palmitic acid, palmitoleic 
acid, stearic acid, oleic acid methyl ester and linoleic acid. 
Wavenumber calibration and baseline correction were 
used for pre-processing the Raman spectra before being 
clustered into CAS, representing tumor and non-tumor 
groups. Each CAS was input to the compositional analysis 
using the reference database, and it was found that (i) col-
lagen I, collagen III and some lipids are more expressed 
in non-tumor clusters, (ii)  β -carotene was not fitted sig-
nificantly differently in tumor and non-tumor clusters, 
and (iii) the rest of the components are more expressed 
in the tumor clusters. RNA and DNA contents were found 
to be higher in tumor regions compared to non-tumor 
tissue. Inflammation areas (non-tumor) were also found 
to express abundant levels of RNA and DNA. To the best 
of our knowledge, this study represents the first Raman-
based compositional analysis of the main biomolecular 
differences between tumor and non-tumor bladder tissue. 
 In 2007, Stone and colleagues  [54] continued on from 
this work to determine the biochemical differences asso-
ciated with different bladder pathological groups. Con-
ventional Raman spectra were obtained from 73 patient 
samples  in vitro consisting of five different bladder pathol-
ogy groups; normal, cystitis, CIS, G1/G2 TCC and G3 TCC. 
All samples were obtained during TURP and TURBT, 
snap-frozen and stored at -80 ° C, before returning to room 
temperature for measurement. These spectra were sub-
jected to compositional analysis using a reference data-
base similar to that used by de Jong et al.  [45] . To generate 
the reference database, Raman spectra were obtained 
from the following constituents; actin,  β -carotene, colla-
gen I, collagen III, triolein, choline, oleic acid, DNA and 
cholesterol. Raman spectra from the different bladder 
 Figure 10   Raman map (A) and digital image stained with H&E (B) of a section of normal bladder tissue showing similarities between tissue 
regions. Images obtained from de Jong et al.  [52] , reproduced with permission from Elsevier. 
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pathologies were initially pre-processed, and then fitted 
to the reference database using OLS. Results of this study 
can be seen in  Figure 11 , which shows an increase in DNA 
content as the bladder tissue progresses from normal to 
malignant. An increase is also seen with cholesterol, 
choline, oleic acid and triolein with tissue progression. 
Actin levels vary throughout the pathological groups, 
and there is a decrease in both collagen I and collagen III 
with disease progression. This mirrors the biochemical 
information gathered by de Jong et al.  [45] and similarly 
enables a better understanding of the progress of bladder 
disease which could potentially be used to eliminate intra- 
and inter-observer error in histopathology. 
 In 2009, Grimbergen et al.  [11] investigated the effects 
of the photosensitive drug 5-ALA on the biochemical 
analysis of bladder tissue using conventional Raman 
spectroscopy. The motivation for this study was the poten-
tial improvement in the diagnostic capability of bladder 
pathology by combining Raman spectroscopy and fluores-
cent imaging, the latter enabling a more targeted appli-
cation of the former. Raman spectra were obtained from 
benign and malignant bladder samples both with and 
without the presence of 5-ALA (92 biopsies from 73 patients 
without 5-ALA and 38 biopsies from 19 patients with 
5-ALA), whereby benign samples represented normal and 
cystitis, and malignant samples included CIS, G1 TCC, G2 
TCC and G3 TCC. From the recorded spectra, it was noted 
that the key spectral regions for discriminating between 
the biochemistry of benign and malignant bladder tissue 
samples in the presence of 5-ALA were found over the 
following ranges: 422 – 466, 530 – 574, 634 – 698, 1030 –
 1070, 1170 – 1200, 1250 – 1290, 1400 – 1480 and 1550 – 1610 
cm -1 . However, since the goal of 5-ALA is to increase the 
concentration of the photosensitizer PpIX in the cancer-
ous tumor regions, it is possible that this photosensitizer 
is affecting the biochemistry of the tissue, resulting in 
alterations to the Raman spectra obtained with 5-ALA 
in comparison to those without any photosensitizer. So 
whilst this study has shown the potential application of 
Raman spectroscopy with fluorescence for discriminat-
ing between the biochemistry of benign and malignant 
bladder tissue, it should be noted that the differences that 
were observed do not reflect the same molecular differ-
ences that are seen in the biochemistry of bladder samples 
without 5-ALA. Despite this, there is still significant evi-
dence to show that the combination of Raman spectros-
copy with fluorescence-guided cystoscopy could be used 
to improve the diagnosis of bladder cancer. 
 In 2010, Draga and colleagues  [8] investigated the 
feasibility of using a Raman spectroscopic probe to 
detect differences in the biochemistry of benign and 
malignant bladder tissue  in vivo with a high-volume 
fiber-optic probe, and also to be able to determine 
the invasiveness of the disease. Raman spectra were 
obtained from normal and cancerous (graded Ta, T1 and 
T2 by experienced pathologists) bladder lesions, from 38 
patients,  in vivo during TURBT procedures with integra-
tion times between 1 – 5 s. From these spectra, the most 
prominent peaks found in normal bladder tissue were 
at 875, 1080, 1289, 1303, 1446 and 1657 cm -1 which relate 
to lipids and proteins, with the peak at 875  cm -1 repre-
senting hydroxyproline, an important component of col-
lagen. Peaks found in the bladder cancer spectra were 
at 680, 789, 1003, 1170, 1180, 1208, 1370, 1386, 1560 and 
1610 cm -1 , mainly associated with amino acids (such as 
phenylalanine and tryptophan) and DNA. This agrees 
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 Figure 11   Bar graph representing the data presented by Stone et al.  [54] showing the relative concentrations of each constituent associ-
ated with each bladder pathology. 
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with previous studies where a decrease in collagen and 
an increase in DNA and lipids is observed as tissue pro-
gresses from normal to cancerous. Inflammation was 
distinguished from normal and cancer tissue in the fol-
lowing wavenumber peaks: 562, 572, 1485 and 1569 cm -1 . 
 A further breakdown of the spectral peaks observed 
can be seen in Table 15. The high-volume Raman probe 
used in this study measured up to a depth of 2 mm which 
means that most of the signal collected was from the sub-
mucosa and muscle layer, with significantly less contri-
bution coming from the submucosal fatty layers. It was 
proposed, therefore, that the spectral features of lipids 
observed could potentially be used to assess the invasive-
ness of the tumor. This study achieved, for the first time, 
the goal of investigating the biochemistry of different 
bladder tissue pathologies  in vivo using a real-time, non-
destructive method in a clinical setting and will undoubt-
edly pave the way for the future development of novel 
fiber-optic Raman probes that will aid in the understand-
ing of the etiology of bladder cancer. 
 Most recently, in 2011, as part of a proof-of-concept 
study using bladder tissue, Shapiro et  al.  [12] applied 
Raman spectroscopy to deparaffinized bladder samples 
(three normal samples, six with Ta, four with T2 and two 
samples with TIS; obtained from cystectomy and prosta-
tectomy procedures) to acquire Raman spectra for each 
pathology. From these spectra, a distinct peak was found 
at 1584  cm -1 that is only present in bladder carcinoma 
tissue, which had not been previously reported. Raman 
spectra of both low-grade and high-grade cancer show 
this peak at 1584 cm -1 which was not seen in spectra from 
benign tissue. It was also reported that the height of this 
peak correlated with the carcinoma grade of the tissue, 
however the peak was not assigned to any particular bio-
molecular components. This distinctive peak seems to not 
only be an excellent method for the diagnosis of bladder 
cancer, but also for determining the associated pathologi-
cal grade. 
6   Conclusion and future 
developments 
 It is clear from the results reviewed in this paper that there 
is growing potential for the application of Raman spec-
troscopy to the study of urinary bladder disease in order 
to improve patient treatment and patient outcome. The 
technique can be applied in a number of different forms, 
including conventional Raman microspectroscopy, as well 
as using fiber-optic probes. Raman microspectroscopy 
has been shown to be a strong candidate for improving 
the diagnostic sensitivity and specificity of bladder cytol-
ogy, with particular interest for the case of low-grade 
cancer cells, for which a recent (and the first) patient 
study showed a sensitivity and specificity of 92% and 
91% respectively. Raman fibers have been shown to return 
similar results for both  in vitro / ex vivo and  in vivo samples. 
The improvement in sensitivity over existing diagnostic 
procedures is not only due to the additional biochemi-
cal information provided by the Raman spectrum and the 
ability to classify this using multivariate diagnostic algo-
rithms, but it is also partially due to the reduction in inter- 
and intra-observer variation, which can vary by up to 
45 – 50% using current clinical methods  [20, 56] . As well as 
improved diagnostic accuracy, Raman spectroscopy also 
enables an estimation of the biomolecular composition 
of tissue and cell samples, therefore facilitating further 
understanding of the etiology of bladder disease and the 
biochemical continuum of disease progression. 
 Despite the various positive results presented in this 
paper, it should be noted that the use of Raman spectros-
copy for bladder diagnostics is not without its problems. 
While the method has been demonstrated to produce 
accurate results in real time, further development is nec-
essary to ensure that these systems are sufficiently robust 
for everyday medical usage. Presently, the application of 
Raman microspectroscopy to cells and tissue requires an 
experienced hand and there are numerous practical issues 
that need to be addressed, for example the 3-D point in a 
cell from which the spectrum is acquired is important, as 
is the need to periodically calibrate the system for wave-
length shifts. 
 Acquisition time is usually in the order of 30 s which 
can be an issue if many cells or tissue locations are to be 
examined, and different substrates (or fibers) can provide 
different background signals that can provide sharply 
varying results. Praveen et al.  [49] recently applied mod-
ulated Raman spectroscopy, a method used to remove 
unwanted background signals from Raman spectra, with 
a significantly reduced acquisition time (6 s per measure-
ment), and was able to completely discriminate between 
healthy and cancerous cells. Whilst this study has shown 
that it may be possible to develop high throughput cell 
screening methods with this technique, there are other 
experimental parameters which need to be considered to 
fully optimize the application of Raman spectroscopy for 
cancer diagnostics. 
 The lack of standardization, in terms of equipment, 
consumables and methodologies has resulted in the 
recording of significantly differing spectra in the studies 
to date and this has prevented the use of training datasets 
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being shared across research groups and has inhibited 
the comparison of results in a controlled manner. Even 
identical systems and methodologies can produce moder-
ately varying spectra for the same sample, which may be 
attributed to the relatively strong noise signal and varia-
tion in experimental settings on a precise scale. If Raman 
spectroscopy is ever to become an everyday clinical tool it 
is essential that a standardized procedure will be estab-
lished in order to overcome these inconsistencies. One 
solution may be an automation of the process insofar as 
possible in order to reduce user variability. 
 While it is essential for further research and develop-
ment to focus on minimizing problems relating to con-
sistency, it is expected that the areas that will receive the 
greatest attention going forward will be Raman cystos-
copy and Raman cytology. Raman cytoscopy probes not 
only have the potential to detect and classify the presence 
of disease, but they may also be applied during surgical 
procedures to “map” regions of disease versus healthy 
tissue as well as profiling the depth of the tumor. It is 
most likely that numerous research groups will attempt to 
design Raman fiber-optic probes that overcome the prob-
lems of being too large and providing a too weak signal. 
 One of the greatest problems that needs to be over-
come is the strong background signal from the fiber itself. 
A strong candidate for solving these problems is photonic 
crystal fibers. These recently developed fibers could be 
used to overcome the technical challenge of packing mul-
tiple fibers into a small probe and because they employ a 
hollow core, and in addition these fibers do not add any 
contribution to the Raman signal like those seen with silica 
fibers  [29] . Another possible solution is the combination of 
modulated Raman spectroscopy with a fiber-optic probe 
which has been shown to suppress the fluorescent back-
ground signals generated within the fiber, thus allowing 
for greater fidelity of the Raman signal  [28] . Many more  in 
vivo Raman cysto scopy experiments are expected in the 
near future. 
 Similarly, further progress could be made to improve 
Raman cytology. Following from the first patient study 
based on cells obtained from voided urine in 2011  [12] , 
which demonstrated promising results, it is expected 
that similar studies will try to build on this. One avenue 
of research will be the application of modulated Raman 
spectroscopy in a patient study to improve on the diag-
nostic accuracy achieved with conventional Raman 
microspectroscopy. Another possibility is the applica-
tion of surface-enhanced Raman spectroscopy (SERS) to 
bladder cells. SERS is a technique used to amplify the 
Raman signal from cells (or tissue), as explained in more 
detail in  [57] , which has the potential to be integrated into 
a point-of-care device for rapid cell analysis and diagno-
sis. A simple approach is to mix a solution of cells with 
a solution of gold nanoparticles, and in regions of the 
cell where aggregations of nanoparticles occur, it is pos-
sible to obtain a significantly (approximately million fold) 
enhanced Raman signal. Though SERS is known to have 
problems regarding reproducibility, it has been recently 
applied to urine samples for point-of-care diagnosis of 
urinary tract infections  [58] , and may have the potential to 
be further developed to detect other urinary diseases. One 
of the great advantages that such an approach may have 
would be the relatively strong power of the Raman signal 
which would therefore allow for a much shorter acquisi-
tion time. This feature may facilitate the use of microflu-
idic channels to detect the spectra from fast moving cells 
in a urine sample. Another possibility for future research 
is the automation of Raman spectroscopy for cytology, 
which involves specialist digital image processing tech-
niques to detect the nucleus within “suspicious” cells, 
obtaining Raman spectra from these targeted nuclei, and 
using diagnostic algorithms to classify the pathological 
state of the cells being measured. Recently the first such 
automated system has been developed  [59] in the form of 
a user friendly graphical user interface which has been 
applied successfully for cervical cancer screening. It may 
be possible to integrate a similar system into bladder 
cancer diagnostics to automate (and standardize) the 
Raman spectroscopic method. 
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